

Objection Deadline: February 2, 2021 @ 12:00 p.m. (ET)

**UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> , ¹	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

**FIFTEENTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD OF NOVEMBER 1, 2020 THROUGH NOVEMBER 30, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant’s Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	November 1, 2020	November 30, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$534,328.40 (80% of \$667,910.50)	
Total expenses requested in this statement:	\$3.32	
Total fees and expenses requested in this statement:	\$534,331.72	
This is a(n): X Monthly Application Interim Application Final Application		

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD NOVEMBER 1, 2020 THROUGH NOVEMBER 30, 2020**

PROFESSIONAL	TITLE	RATE	HOURS	FEES
Lisa Donahue	Managing Director	\$1,195	13.4	\$ 16,013.00
Richard Collura	Managing Director	\$1,090	16.8	18,312.00
Jesse DelConte	Director	\$950	136.4	129,580.00
Kevin M McCafferty	Director	\$950	169.7	161,215.00
Mark F Rule	Director	\$910	2.4	2,184.00
Gabe J Koch	Director	\$840	49.8	41,832.00
HS Bhattal	Director	\$840	34.2	28,728.00
Sam J Canniff	Senior Vice President	\$645	30.2	19,479.00
Kristina Galbraith	Senior Vice President	\$645	3.0	1,935.00
Kaitlyn A Sundt	Senior Vice President	\$510	1.5	765.00
Andrew D DePalma	Vice President	\$515	149.5	76,992.50
Lan T Nguyen	Vice President	\$515	122.2	62,933.00
Sam K Lemack	Vice President	\$515	134.1	69,061.50
Nate A Simon	Vice President	\$515	56.0	28,840.00
Tammy Brewer	Vice President	\$450	11.5	5,175.00
Melanie McCabe	Vice President	\$415	9.7	4,025.50
Roy Ellis Ochoa	Consultant	\$420	2.0	840.00
Total Professional Hours and Fees			942.4	\$ 667,910.50
Less 50% Travel Fees				-
Subtotal				\$ 667,910.50
Less 20% Holdback				(133,582.10)
Invoice Total				\$ 534,328.40
			Average Billing Rate	\$ 708.73

ALIXPARTNERS, LLP

SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD NOVEMBER 1, 2020 THROUGH NOVEMBER 30, 2020

CODE	MATTER CATEGORY	HOURS	FEES
101	Chapter 11 Process/Case Management	65.4	\$ 51,127.00
103	Cash Management	217.3	117,910.50
104	Communication with Interested Parties	50.4	34,743.00
105	U.S. Trustee / Court Reporting Requirements	21.5	11,725.00
106	Business Analysis & Operations	385.6	322,740.00
107	POR Development	34.7	20,298.50
110	Special Projects	65.7	34,225.50
112	Retention and Engagement Administration	1.1	740.50
113	Fee Statements and Fee Applications	33.5	20,225.50
114	Court Hearings	13.6	12,227.00
115	Forensic Analysis	53.6	41,948.00
		942.4	\$ 667,910.50
		Average Billing Rate	\$ 708.73

AlixPartners, LLP (“AlixPartners”), as financial advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Fifteenth Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period November 1, 2020 through November 30, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 528] and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

[Remainder of page intentionally left blank.]

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$667,910.50, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$3.32, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$534,328.40 (80% of \$667,910.50) and expenses in the amount of \$3.32, for a total amount of \$534,331.72.

Dated: January 19, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

AlixPartners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/02/20	SKL	Finalize remaining updates to the September flash report and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.50
11/02/20	HSB	Review KEIP motion draft prepared by Davis Polk and prepared notes with updates for recent financial performance	0.60
11/03/20	HSB	Weekly professionals call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, L. Donahue, G. Koch and H. Bhattal (all AlixPartners) re: catch up and planning.	0.50
11/03/20	LJD	Weekly professionals call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, L. Donahue, G. Koch and H. Bhattal (all AlixPartners) re: catch up and planning.	0.50
11/03/20	GJK	Weekly professionals call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, L. Donahue, G. Koch and H. Bhattal (all AlixPartners) re: catch up and planning.	0.50
11/03/20	JD	Weekly professionals call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, L. Donahue, G. Koch and H. Bhattal (all AlixPartners) re: catch up and planning.	0.50
11/03/20	JD	Prepare agenda for weekly professionals call.	0.30
11/05/20	SKL	Review latest October flash report for financials relevant to the KEIP/KERP draft response and update list of key metrics and source info accordingly.	1.90
11/05/20	HSB	Review FTI correspondence and list of requested items	0.20
11/05/20	HSB	Review summary status of Purdue pipeline assets	0.30
11/06/20	ADD	Call with H. Bhattal, A. DePalma, L. Donahue, G. Koch, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re:	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		weekly update call.	
11/06/20	HSB	Call with H. Bhattal, A. DePalma, L. Donahue, G. Koch, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call.	0.40
11/06/20	HSB	Prepare notes and agenda for update call with case related developments	0.30
11/06/20	KM	Call with H. Bhattal, A. DePalma, L. Donahue, G. Koch, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call.	0.40
11/06/20	LTN	Call with H. Bhattal, A. DePalma, L. Donahue, G. Koch, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call.	0.40
11/06/20	SKL	Finalize review of additional new vendors and invoices provided by C. MacDonald (Purdue) and update the accounts payable database accordingly.	1.10
11/06/20	LJD	Call with H. Bhattal, A. DePalma, L. Donahue, G. Koch, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call.	0.40
11/06/20	GJK	Call with H. Bhattal, A. DePalma, L. Donahue, G. Koch, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call.	0.40
11/06/20	NAS	Call with H. Bhattal, A. DePalma, L. Donahue, G. Koch, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call.	0.40
11/09/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: trust transfer process.	0.30
11/09/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: trust transfer process.	0.30
11/09/20	JD	Correspondence with Davis Polk re: trust transfer call.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/10/20	JD	Call with M. Kesselman (Purdue), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly catch up call.	0.80
11/10/20	NAS	Review Purdue media report.	0.30
11/10/20	LJD	Call with M. Kesselman (Purdue), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly catch up call.	0.80
11/10/20	HSB	Call with M. Kesselman (Purdue), M. Huebner, C. Robertson, E. Vonnegut (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly catch up call.	0.80
11/11/20	HSB	Review debtor statement filed re: payment by the Sackler families to DOJ	0.20
11/11/20	ADD	Call with J. DelConte, G. Koch, A. DePalma (all AlixPartners), Z. Levine, A. Lele, E. Diggs (all Davis Polk) re: trust transfer process.	0.50
11/11/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: trust transfer process.	0.20
11/11/20	GJK	Call with J. DelConte, G. Koch, A. DePalma (all AlixPartners), Z. Levine, A. Lele, E. Diggs (all Davis Polk) re: trust transfer process.	0.50
11/11/20	JD	Create agenda for weekly call tomorrow with management.	0.40
11/11/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: trust transfer process.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/11/20	JD	Correspondence with Jefferies and A. DePalma (AlixPartners) re: IQVIA data.	0.20
11/11/20	JD	Call with J. DelConte, G. Koch, A. DePalma (all AlixPartners), Z. Levine, A. Lele, E. Diggs (all Davis Polk) re: trust transfer process.	0.50
11/11/20	JD	Call with R. Aleali (Purdue) re: trust transfer workstream.	0.50
11/12/20	JD	Call with C. Landau, M. Kesselman, R. Aleali, J. Lowne (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly update and planning meeting.	0.70
11/12/20	JD	Review 9019 objections filed on the docket.	1.20
11/12/20	JD	Call with J. DelConte and A. DePalma (both AlixPartners) re: open diligence and trust transfer workstreams.	0.40
11/12/20	LJD	Review agenda for Purdue weekly update call with management and advisors	0.20
11/12/20	LJD	Call with C. Landau, M. Kesselman, R. Aleali, J. Lowne (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly update and planning meeting.	0.70
11/12/20	SKL	Update conversation with H. Bhattal, S. Lemack (both AlixPartners) on various case related matters.	0.70
11/12/20	ADD	Call with J. DelConte and A. DePalma (both AlixPartners) re: open diligence and trust transfer workstreams.	0.40
11/12/20	HSB	Review objection of ad hoc group of non-consenting states to debtors' settlement with DOJ	0.30
11/12/20	HSB	Review objection of ad hoc Committee on Accountability to debtors' settlement with DOJ	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/12/20	HSB	Review motion filed by third party (as amici curiae) in opposition to debtors' settlement with DOJ	0.10
11/12/20	HSB	Call with C. Landau, M. Kesselman, R. Aleali, J. Lowne (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner, T. Melvin (all PJT), L. Donahue, H. Bhattal, J. DelConte (all AlixPartners) re: weekly update and planning meeting.	0.70
11/12/20	HSB	Update conversation with H. Bhattal, S. Lemack (both AlixPartners) on various case related matters.	0.70
11/13/20	HSB	Prepare notes and agenda for update call with case related developments	0.20
11/13/20	HSB	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.70
11/13/20	ADD	Review and reconcile assigned contract list to Rhodes Tech Executed Agreement List.	1.20
11/13/20	LTN	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.70
11/13/20	SKL	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.70
11/13/20	LJD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.70
11/13/20	LJD	Review fee application and comment	1.50
11/13/20	GJK	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.70
11/13/20	JD	Review supplemental KEIP order draft.	0.40
11/13/20	JD	Review agenda for today's AlixPartners call.	0.20
11/13/20	JD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, L. Nguyen (all AlixPartners) re: weekly update	0.70
11/16/20	JD	Review materials and correspondence from Purdue and	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Davis Polk re: unclaimed property.	
11/16/20	JD	Review draft CDA mark-up for third party discussions.	0.20
11/16/20	JD	Review latest KEIP Reply brief to be filed prior to the hearing.	0.50
11/16/20	HSB	Review proposed order filed by Davis Polk re: 9019 settlement between the debtors & DOJ	0.30
11/16/20	HSB	Review Third Monitor Report	0.40
11/16/20	HSB	Review Davis Polk's stipulation of settlement re: production of privileged documents to UCC	0.20
11/17/20	HSB	Review supplemental reply filed by Davis Polk re: KERP	0.20
11/17/20	JD	Review insurance chart for trust transfer process.	0.30
11/17/20	NAS	Review motions and press related to DOJ settlement.	1.30
11/17/20	LJD	Review UCC presentation and comment	1.50
11/18/20	JD	Correspondence with G. Koch (AlixPartners) re: trust transfer process.	0.20
11/18/20	JD	Review and comment on agenda for call tomorrow morning.	0.20
11/18/20	JD	Correspondence with PJT, Davis Polk and Purdue re: third party discussions.	0.40
11/18/20	HSB	Review correspondence re: diligence request and coordination	0.10
11/19/20	LJD	Board debrief call with K. Buckfire (Board Member)	0.50
11/20/20	LJD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.70
11/20/20	LJD	Update call with K. Buckfire (Board Member)	0.30
11/20/20	SKL	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) re: weekly update call	
11/20/20	NAS	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.70
11/20/20	NAS	Correspondence with G. Koch (AlixPartners) and J. DelConte (AlixPartners) re: draft of transfer workplan.	0.40
11/20/20	NAS	Review motions related to production of privileged documents.	1.00
11/20/20	NAS	Revise transfer workplan following feedback from G. Koch (AlixPartners).	2.10
11/20/20	GJK	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.70
11/20/20	JD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.70
11/20/20	JD	Review and provide comments on AlixPartners call agenda.	0.20
11/20/20	KM	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.70
11/20/20	HSB	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.70
11/20/20	HSB	Prepare notes and agenda for update call with case related developments	0.20
11/20/20	LTN	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, L. Nguyen, N. Simon (all AlixPartners) re: weekly update call	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/23/20	JD	Call with G. Koch, J. DelConte, N. Simon, S. Lemack (all AlixPartners), R. Aleali, K. McCarthy, B. Miller (all Purdue), C. Robertson, A. Lele and E. Diggs (all DPW) to review Purdue transfer workplan.	0.50
11/23/20	GJK	Call with G. Koch, J. DelConte, N. Simon, S. Lemack (all AlixPartners), R. Aleali, K. McCarthy, B. Miller (all Purdue), C. Robertson, A. Lele and E. Diggs (all DPW) to review Purdue transfer workplan.	0.50
11/23/20	GJK	Debrief with G. Koch, N. Simon, S. Lemack (all AlixPartners) following transfer workplan call with DPW and Purdue.	0.30
11/23/20	GJK	Coordinate and plan for transfer work plan.	1.50
11/23/20	NAS	Research 2018-2019 compensation question from C. Oluwole (DPW) and C. Dysard (Spears & Imes).	1.40
11/23/20	NAS	Draft transfer workplan notes from AlixPartners/DPW/Purdue to distribute to team.	0.20
11/23/20	NAS	Call with C. Oluwole (DPW) and C. Dysard (Spears & Imes) to discuss questions related to 2018-2019 compensation schedules.	0.20
11/23/20	NAS	Research SmartSheet functionality to use for Purdue transfer PMO workstream.	0.80
11/23/20	NAS	Call with G. Koch, J. DelConte, N. Simon, S. Lemack (all AlixPartners), R. Aleali, K. McCarthy, B. Miller (all Purdue), C. Robertson, A. Lele and E. Diggs (all DPW) to review Purdue transfer workplan.	0.50
11/23/20	NAS	Debrief with G. Koch, N. Simon, S. Lemack (all AlixPartners) following transfer workplan call with DPW and Purdue.	0.30
11/23/20	SKL	Call with G. Koch, J. DelConte, N. Simon, S. Lemack (all AlixPartners), R. Aleali, K. McCarthy, B. Miller (all	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Purdue), C. Robertson, A. Lele and E. Diggs (all DPW) to review Purdue transfer workplan.	
11/23/20	SKL	Debrief with G. Koch, N. Simon, S. Lemack (all AlixPartners) following transfer workplan call with DPW and Purdue.	0.30
11/24/20	SKL	Review Smartsheets set-up for project Catalyst and begin preparing list of updates to incorporate the latest Purdue transfer workplan.	1.80
11/24/20	LJD	Call with L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, T. Coleman, T. Melvin, J. Turner (all PJT) re: weekly check in and go-forward planning.	0.60
11/24/20	NAS	Review press related to Purdue guilty plea.	0.60
11/24/20	NAS	Review notes/action items related to transfer workplan.	0.40
11/24/20	JD	Call with L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, T. Coleman, T. Melvin, J. Turner (all PJT) re: weekly check in and go-forward planning.	0.60
11/24/20	HSB	Call with L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, T. Coleman, T. Melvin, J. Turner (all PJT) re: weekly check in and go-forward planning.	0.60
11/24/20	HSB	Review excel summary of sales data prepared by A. DePalma (AlixPartners)	0.30
11/25/20	HSB	Review excel summary of sales data	0.10
11/25/20	JD	Review staffing planning for potential tax modeling work stream.	0.30
11/25/20	JD	Review ordinary course professional summary prior to filing.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
11/29/20	NAS	Correspondence with G. Koch (AlixPartners) re: transfer workplan.	0.10
11/30/20	NAS	Review Smartsheet project management examples provided by B. Morey (AlixPartners).	0.80
11/30/20	NAS	Call with G. Koch, N. Simon, S. Lemack (all AlixPartners), and B. Morey (AlixPartners) to review project management Smartsheet tools.	0.30
11/30/20	GJK	Review of set up structure options for Transfer PMO.	2.00
11/30/20	GJK	Call with G. Koch, N. Simon, S. Lemack (all AlixPartners), and B. Morey (AlixPartners) to review project management Smartsheet tools.	0.30
11/30/20	GJK	Correspondence with S Lemack (AlixPartners) re: setting up PMO files for Transfer process.	0.30
11/30/20	SKL	Call with G. Koch, N. Simon, S. Lemack (all AlixPartners), and B. Morey (AlixPartners) to review project management Smartsheet tools.	0.30
11/30/20	JD	Correspondence with G. Koch (AlixPartners) and Davis Polk re: trust transfer work stream.	0.30
11/30/20	JD	Correspondence with PJT re: new dataroom exchange.	0.30
Total			65.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	2.50	515.00	1,287.50
Sam K Lemack	9.50	515.00	4,892.50
Lan T Nguyen	1.80	515.00	927.00
Nate A Simon	11.80	515.00	6,077.00
Gabe J Koch	8.20	840.00	6,888.00
HS Bhattal	9.30	840.00	7,812.00
Kevin M McCafferty	1.10	950.00	1,045.00
Jesse DelConte	12.80	950.00	12,160.00
Lisa Donahue	8.40	1,195.00	10,038.00
Total Hours & Fees	65.40		51,127.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/02/20	JD	Review and provide comments on the latest forecast to actual cash report.	0.40
11/02/20	SKL	Create accounts payable release file.	0.70
11/02/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest feedback re: weekly cash report and begin preparing filing-to-date cash actuals summary.	1.00
11/02/20	SKL	Review and finalize filing-to-date cash actuals summary and circulate internally.	2.10
11/02/20	SKL	Review the week ended 10/24 cash report and provide updated notes and feedback to update accordingly.	2.30
11/02/20	SKL	Review cash actuals feedback and comments prior to afternoon meeting with L. Nguyen (AlixPartners) and prepare notes and updates accordingly.	0.60
11/02/20	HSB	Review weekly cash report prepared by L. Nguyen (AlixPartners) for week ended 10/23/2020 along with underlying excel worksheet	0.70
11/02/20	HSB	Review recent cash activity details prepared by S. Lemack (AlixPartners)	0.20
11/02/20	LTN	Finalize updates to the weekly cash report deck for the week ended 10/23 and circulate for internal sign-off	1.60
11/02/20	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 10/30 cash report	1.60
11/02/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest feedback re: weekly cash report and begin preparing filing-to-date cash actuals summary	1.00
11/02/20	LTN	Prepare cash actual report for Purdue and Rhodes entities post-petition per J. DelConte (AlixPartners) request	1.10
11/03/20	LTN	Update the latest Paysource cash transaction report and categorized for the week ended 10/30 cash report	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/03/20	LTN	Prepare the detailed and summary cash report for Purdue & Rhodes entities for the week ended 10/30	1.20
11/03/20	LTN	Prepare IAC transaction summary and a list of open transactions	1.70
11/03/20	LTN	Reconcile the latest investment activity files and updated the investment section of the week ended 10/30 weekly cash report accordingly	0.40
11/03/20	LTN	Prepare the latest Purdue forecast to actual variance analysis for week ended 10/30	1.40
11/03/20	HSB	Review Purdue management presentation with most Sept 2020 year to date financial information for Purdue	0.70
11/03/20	HSB	Review excel file with long term projections prepared by Purdue management with latest estimates as of Aug 2020	0.70
11/03/20	SKL	Create accounts payable release file.	0.70
11/03/20	JD	Review cash actuals since filing for both Rhodes and Purdue. Review for recent and year-over-year trends.	1.40
11/03/20	JD	Call with J. Lowne (Purdue) re: business plan presentations.	0.30
11/04/20	SKL	Create accounts payable release file.	0.80
11/04/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest feedback re: week ended 10/30 cash report	1.00
11/04/20	SKL	Review latest feedback provided by E. Nowakowski and R. Brown (both Purdue) and put together updated payroll cash summary accordingly.	1.60
11/04/20	SKL	Review latest updates made to the Restructuring Professional fee tracker based on latest fee applications filed.	1.80
11/04/20	SKL	Review latest updates made to the Retain Professional fee	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		tracker based on latest fee applications filed.	
11/04/20	SKL	Update critical vendor form based on feedback provided by H. Benson (Purdue) and circulate to R. Haberlin (Purdue) for final sign-off.	0.60
11/04/20	HSB	Review UCC and NCSG statement in response to the Sackler motion for approval of payment to DOJ	0.20
11/04/20	HSB	Review excel file with OCP tracking	0.30
11/04/20	HSB	Attend Business Development Budget call with Purdue management team members	0.10
11/04/20	HSB	Review Business Development Budget presentation prepared by Purdue management	0.20
11/04/20	LTN	Review the latest fee applications filed by restructuring and retained professionals from the docket and update our tracker	2.20
11/04/20	LTN	Begin reconciliation of the latest professional and retained professional fee applications vs the 13-week cash forecast	1.70
11/04/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest feedback re: week ended 10/30 cash report	1.00
11/04/20	LTN	Correspondence to various Purdue teams re: additional details on cash transactions for the week ended 10.30	0.80
11/05/20	LTN	Update the restructuring fee tracker to include the forecast of next year	1.30
11/05/20	SKL	Review latest feedback provided by J. Beck-Sechow (Purdue) re: payroll activity and update the forecast-to-actuals variance notes and cash report accordingly.	1.20
11/05/20	SKL	Prepare list of responses and feedback re: open cash items, and circulate internally.	0.40
11/05/20	SKL	Finalize remaining critical vendor updates and circulate	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/05/20	SKL	update accordingly re: latest critical vendor inquiry. Review latest list of vendors and invoices provided by C. MacDonald (Purdue) and update the vendor master and AP process accordingly to include in upcoming release batch.	1.10
11/05/20	SKL	Finalize review of updates made to the Restructuring Professional fee tracker in preparations to update the Purdue 13-week cash forecast.	1.50
11/05/20	SKL	Finalize review of updates made to the Retained Professional fee tracker in preparations to update the Purdue 13-week cash forecast.	1.00
11/05/20	SKL	Create accounts payable release file.	0.80
11/05/20	JD	Review correspondence re: open cash forecast questions.	0.20
11/06/20	SKL	Create accounts payable release file.	0.70
11/06/20	LTN	Review feedbacks provided by R. Brown, C. Hobbick and T. Gabriele (all Purdue) and updated the cash report week ended 10/30 accordingly	1.30
11/06/20	LTN	Continue updating the latest Purdue & Rhodes forecast to actual variance analysis for week ended 10.30	1.40
11/06/20	LTN	Prepare slides for the cash actual report for the week ended 10/30	0.90
11/09/20	LTN	Finalize deck for the weekly cash report for week ended 10.30 and circulate for the internal review	1.70
11/09/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to discuss latest updates re: week ended 10/30 cash report.	0.70
11/09/20	LTN	Begin updating the latest 13-week cash forecast as of 11/06 and carry forward all cash summaries for Purdue	2.00
11/09/20	LTN	Download AR data from SAP and update the receipts section of Purdue and Rhodes 13-week cash forecast as of	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		11/06	
11/09/20	LTN	Download AP data from SAP and update the expenses of Purdue and Rhodes 13-week cash forecast as of 11/06	1.70
11/09/20	LTN	Prepare the customer receipts section of the Purdue 13 week cash forecast based on the latest sales forecast provided by J. Knight (Purdue)	1.30
11/09/20	HSB	Review weekly cash report prepared by L. Nguyen (AlixPartners) for week ended 10/30/2020 along with underlying excel worksheet	0.80
11/09/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to discuss latest updates re: week ended 10/30 cash report.	0.70
11/09/20	SKL	Create accounts payable release file.	0.70
11/09/20	SKL	Review latest quarterly UST fee calculation and circulate per UST request.	0.40
11/09/20	SKL	Review and reconcile latest list of open cash inquiries and prepare updated breakdown and request to R. Brown (Purdue).	1.40
11/09/20	SKL	Review and reconcile latest OCP cash transactions and provided updated list of open items to C. MacDonald (Purdue).	0.60
11/09/20	SKL	Review and finalize remaining updates to the week ended 10/30 cash report and circulate internally for final sign-off.	2.30
11/09/20	SKL	Review latest critical vendor updates and circulate follow-up request to R. Haberlin (Purdue) for final sign-off.	0.50
11/09/20	JD	Review draft cash report from last week.	0.40
11/10/20	SKL	Finalize updates to the week ended 10/30 cash report based on latest feedback received and re-circulated for final sign-off.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/10/20	SKL	Review and reconcile latest MCO rebate tracker provided by D. Krishan (Purdue) and update the Purdue cash forecast accordingly.	1.70
11/10/20	SKL	Review the latest EastWest cash transaction report provided by T. Gabriele (Purdue) and update categorizations accordingly.	2.20
11/10/20	SKL	Review latest IAC cash activity and update the Purdue and Rhodes IAC cash summaries based on the latest feedback provided by R. Brown (Purdue).	1.30
11/10/20	SKL	Create accounts payable release file.	0.70
11/10/20	LTN	Prepare the operating expense section of Purdue 13-week cash forecast as of 11/06	1.90
11/10/20	LTN	Finalize updates to the customer receipts section of the Purdue forecast as of 11/06	1.40
11/10/20	LTN	Prepare the IAC receipts and IAC disbursements section of the Purdue forecast as of 11/06	1.90
11/10/20	LTN	Finalize the latest restructuring fee applications and update the Purdue 13-week cash forecast as of 11/06	2.00
11/10/20	LTN	Finalize the latest retained professional fee applications and update the Purdue 13-week cash forecast as of 11/06	1.70
11/11/20	LTN	Begin updating the latest 13-week cash forecast as of 11/06 and carry forward all cash balances for Rhodes	2.50
11/11/20	LTN	Update the Operating section of the Rhodes 13-week cash forecast as of 11/06	1.80
11/11/20	LTN	Update the customer receipts section of the Rhodes 13-week cash forecast as of 11/06	1.50
11/11/20	LTN	Update the IAC receipts and IAC disbursements section of the Rhodes 13-week cash forecast	2.00
11/11/20	SKL	Create accounts payable release file.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/11/20	SKL	Review and reconcile the latest Paysource cash transaction report and update the cash transactions accordingly.	1.90
11/11/20	SKL	Review latest customer rebate payments and update and footnote the latest weekly cash report accordingly.	1.40
11/11/20	SKL	Review the Operating Expense and Customer Receipt section of the latest Purdue 13-week cash forecast and provide updates and feedback accordingly.	2.10
11/11/20	JD	Review updated cash forecast to actual analysis.	0.20
11/12/20	SKL	Review and reconcile IAC summaries in the latest Purdue and Rhodes cash forecast and provided updates and feedback accordingly.	1.00
11/12/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest sales forecast provided by J. Knight (Purdue).	0.50
11/12/20	SKL	Create accounts payable release file.	0.70
11/12/20	SKL	Prepare for and participate in meeting with H. Benson and B. Sielert (Purdue) re: AP review process.	0.90
11/12/20	SKL	Finalize remaining updates to the week ended 11/06 cash report and circulate list of open items to R. Brown (Purdue) for additional info and feedback.	2.00
11/12/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest sales forecast provided by J. Knight (Purdue)	0.50
11/12/20	HSB	Review relevant sections of advisory firms' engagement letters and fee applications for purposes of determining certain estimates for 13-week cash forecasts	0.80
11/12/20	HSB	Review latest version of minimum cash calculation.	0.20
11/12/20	HSB	Review case professional fee forecast spreadsheet for	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		purposes of determining certain estimates for 13-week cash forecasts	
11/13/20	LTN	Continue to update other sections of the Purdue 13-week cash forecast as of 11/06 and finalize the cash summaries	2.40
11/13/20	LTN	Continue to update other sections of the Rhodes 13 week cash forecast as of 11/06 and finalize the cash summaries	1.50
11/13/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates and feedback re: Purdue and Rhodes 13-week forecasts	1.50
11/13/20	SKL	Create accounts payable release file.	0.70
11/13/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates and feedback re: Purdue and Rhodes 13-week forecasts.	1.50
11/13/20	SKL	Review and reconcile latest fee applications filed on the docket and update and finalize the restructuring professional forecast accordingly.	2.30
11/13/20	SKL	Review and reconcile latest fee applications filed on the docket and update and finalize the retained professional forecast accordingly.	2.10
11/13/20	SKL	Finalize review of the Rhodes cash forecast and provide updated feedback and comments accordingly.	1.40
11/16/20	SKL	Create accounts payable release file.	0.70
11/16/20	SKL	Review the Operating Expense section of the Rhodes cash forecast and provide updated edits and comments.	1.00
11/16/20	SKL	Meeting with D. Krishan (Purdue) and S. Lemack, L. Nguyen (both AlixPartners) to review and discuss the latest MRO rebate tracker.	0.40
11/16/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates to the Purdue 13-week	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		cash forecast.	
11/16/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to continue to finalize updates to the Operating Expense piece of the Purdue cash forecast.	0.80
11/16/20	SKL	Review and reconcile latest MRO rebate tracker provided by D. Krishan (Purdue) and prepare updates to the Purdue cash forecast accordingly.	1.90
11/16/20	SKL	Review and reconcile latest contract cure inquiry provided by H. Benson (Purdue) and circulate update accordingly.	0.50
11/16/20	LTN	Review the latest rebates tracker provided by D. Krishnan (Purdue) and updated the 13-week cash forecast	1.60
11/16/20	LTN	Meeting with D. Krishan (Purdue) and S. Lemack, L. Nguyen (both AlixPartners) to review and discuss the latest MRO rebate tracker.	0.40
11/16/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review and discuss latest updates to the Purdue 13-week cash forecast.	1.40
11/16/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to continue to finalize updates to the Operating Expense piece of the Purdue cash forecast.	0.80
11/16/20	LTN	Finalize the latest 13 week cash forecast beginning 11/06 for Purdue based on feedback and prepared the deck	2.30
11/16/20	LTN	Finalize the latest 13 week cash forecast beginning 11/06 for Rhodes based on feedback and prepared the deck	2.00
11/16/20	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 11/13 cash report	1.50
11/17/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest updates to the Rhodes cash forecast and make updates accordingly	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/17/20	LTN	Prepare the latest Purdue forecast to actual variance analysis for week ended 11/06 and finalized the weekly cash report deck	1.80
11/17/20	LTN	Prepare the latest Rhodes forecast to actual variance analysis for week ended 11/06 and finalized the weekly cash report deck	0.90
11/17/20	LTN	Prepare the latest 13 week cash forecast vs actual summaries, finalized the deck and circulate for internal sign-off	1.50
11/17/20	HSB	Review 13-week cash forecast prepared by L. Nguyen (AlixPartners)	0.80
11/17/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest updates to the Rhodes cash forecast and make updates accordingly.	0.70
11/17/20	SKL	Review latest updated provided by B. Shank (Purdue) re: Customer Deposits and update the Purdue cash forecast accordingly.	1.20
11/17/20	SKL	Review and reconcile the latest Purdue and Rhodes cash forecasts and prepare list of updates and edits.	1.30
11/17/20	SKL	Review and reconcile bank account balance info and finalize updated file for the October Monthly Operating Report.	1.40
11/17/20	SKL	Review and reconcile latest cash activity and finalize monthly disbursements and receipts report for the October Monthly Operating Report.	1.90
11/17/20	SKL	Create accounts payable release file.	0.80
11/17/20	JD	Review latest 13 week cash flow forecast prepared by L. Nguyen and S. Lemack (both AlixPartners).	0.50
11/18/20	JD	Review updated 13 week cash flow forecast. Correspondence with H. Bhattal, S. Lemack and L.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		Nguyen (all AlixPartners) re: same.	
11/18/20	SKL	Create accounts payable release file.	0.70
11/18/20	SKL	Review latest feedback and comments re: forecast-to-actuals variances and circulate updated accordingly.	0.70
11/18/20	SKL	Review and reconcile latest feedback re: third quarter professional interim fee statements and circulate update accordingly.	0.90
11/18/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to finalize updates to the Purdue and Rhodes cash forecasts before circulating.	0.90
11/18/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review feedback and comments provided re: Purdue and Rhodes cash forecast and begin updating accordingly.	0.70
11/18/20	SKL	Finalize review of Rhodes cash forecast and circulate update accordingly re: Rhodes customer rebates.	1.90
11/18/20	SKL	Prepare update to the latest critical vendor inquiry and circulate updated status to the Rhodes team accordingly.	0.60
11/18/20	HSB	Cash forecast discussion with H. Bhattal and L. Nguyen (both AlixPartners)	1.20
11/18/20	HSB	Review year to date actual results versus cash forecasts	0.30
11/18/20	LTN	Reconcile the latest IAC transactions and prepared the updated IAC Summaries for week ended 11/13 cash report	1.50
11/18/20	LTN	Review the docket to calculate the latest KEIP and KERP and updated the payroll and benefits section of the cash forecast	0.80
11/18/20	LTN	Cash forecast discussion with H. Bhattal and L. Nguyen (both AlixPartners)	1.20
11/18/20	LTN	Prepare the Purdue and Rhodes cash summaries for the	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		week ended 11/13 cash actual report	
11/18/20	LTN	Update the 3rd interim fee applications from the docket to the restructuring fee tracker	1.50
11/18/20	LTN	Update the 3rd interim fee applications from the docket to the retained professional fee tracker	0.90
11/18/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to finalize updates to the Purdue and Rhodes cash forecasts before circulating	0.90
11/18/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review feedback and comments provided re: Purdue and Rhodes cash forecast and begin updating accordingly.	0.70
11/18/20	LTN	Update the latest Paysource cash transaction report and categorized for the week ended 11/13 cash report	1.80
11/19/20	LTN	Correspondence with J. Lowne (Purdue) re: KEIP payments and updated the forecast based on his feedback	0.30
11/19/20	LTN	Finalize the 13 week cash forecast beginning 11/06 and the deck based on internal feedback and circulate for sign-off	2.10
11/19/20	LTN	Review the latest feedback by provided by Purdue re: rebates, IAC transactions and updated the week ended 11/13 cash report	1.40
11/19/20	HSB	Review latest changes to 13-week cash forecast prepared by L. Nguyen (AlixPartners)	0.10
11/19/20	SKL	Create accounts payable release file.	0.60
11/19/20	SKL	Review latest feedback and comments re: minimum cash analysis and prepare updated analysis accordingly.	1.80
11/19/20	JD	Review revised and final 13 week cash flow forecast.	0.20
11/20/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		review final updates to the Purdue cash forecast and finalize updates accordingly.	
11/20/20	SKL	Finalize remaining updates to the Purdue cash forecast and forecast-to-actuals and circulate update accordingly for final review and feedback.	2.40
11/20/20	SKL	Finalize remaining updates to the Rhodes cash forecast and forecast-to-actuals and circulate update accordingly for final review and feedback.	1.90
11/20/20	LTN	Prepare the latest Rhodes forecast to actual variance analysis for week ended 11/13 and finalized the weekly cash report deck	1.60
11/20/20	LTN	Prepare the latest Purdue forecast to actual variance analysis for week ended 11/13 and finalized the weekly cash report deck	2.30
11/20/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review final updates to the Purdue cash forecast and finalize updates accordingly.	0.40
11/20/20	LTN	Finalize the deck for the weekly cash report for week ended 11/06 and circulate for the internal sign-off	1.20
11/23/20	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 11/20 cash report	1.50
11/23/20	LTN	Update the latest Paysource cash transaction report and categorized for the week ended 11/20 cash report	1.90
11/23/20	LTN	Finalize the weekly cash report for week ended 11/13 and the deck based on internal feedback and circulate for CFO review	2.00
11/23/20	LTN	Prepare the Purdue and Rhodes cash summaries for the week ended 11/20 cash actual report	1.10
11/23/20	LTN	Reconcile the latest Purdue investment activities and updated the weekly cash report for week ended 11/20	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/23/20	LTN	Prepare a list of transaction inquiries to various Purdue teams and updated their feedback to the week ended 11/20 cash report	1.10
11/23/20	HSB	Discussion with H. Bhattal, S. Lemack (both AlixPartners) re: Purdue cash requirement.	0.10
11/23/20	HSB	Review weekly cash report prepared by L. Nguyen (AlixPartners) for week ended 11/06/2020	0.40
11/23/20	HSB	Review weekly cash report prepared by L. Nguyen (AlixPartners) for week ended 11/13/2020	0.40
11/23/20	SKL	Discussion with H. Bhattal, S. Lemack (both AlixPartners) re: Purdue cash requirement.	0.10
11/23/20	SKL	Create accounts payable release file.	0.90
11/23/20	SKL	Prepare updated critical vendor breakdown and follow-up on outstanding request accordingly.	0.20
11/23/20	JD	Review and provide comments on latest cash forecast to actual reports.	0.40
11/24/20	JD	Review and provide comments on the latest cash forecast to actual report.	0.40
11/24/20	JD	Review initial draft Rhodes product analysis and comments from PJT.	0.50
11/24/20	SKL	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest OCP date provided by C. MacDonald (Purdue) and prepare updated report accordingly	1.20
11/24/20	SKL	Prepare updated breakdown of AHC payment detail post-filling per DPW request.	1.10
11/24/20	SKL	Create accounts payable release file.	0.70
11/24/20	HSB	Review Weekly Sales Report	0.20
11/24/20	HSB	Review cash requirements analysis	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
11/24/20	LTN	Meeting with S. Lemack, L. Nguyen (both AlixPartners) to review latest OCP date provided by C. MacDonald (Purdue) and prepare updated report accordingly	1.20
11/24/20	LTN	Prepare the latest Purdue forecast to actual variance analysis for week ended 11/20 and updated the weekly cash report deck	2.20
11/24/20	LTN	Reconcile the latest IAC transactions and prepared the updated IAC Summaries for week ended 11/20 cash report	1.30
11/24/20	LTN	Prepare the latest Rhodes forecast to actual variance analysis for week ended 11/20 and updated the weekly cash report deck	1.80
11/24/20	LTN	Finalize the deck for the 11/13 weekly cash report and circulate for the internal sign-off	1.50
11/25/20	HSB	Catch up with J. DelConte, S. Lemack and H. Bhattal (all AlixPartners) to review and discuss updates to the Min. Cash Analysis.	0.40
11/25/20	HSB	Review October OCP report.	0.30
11/25/20	HSB	Review weekly cash report prepared by L. Nguyen (AlixPartners) for week ended 11/20/2020	0.70
11/25/20	SKL	Review and reconcile latest weekly sales by product report provided by P. Phouthasone (Purdue) and prepare updated Rhodes weekly sales report accordingly.	1.00
11/25/20	SKL	Review and reconcile latest weekly sales by product report provided by E. Nowakowski (Purdue) and prepare updated Purdue weekly sales report accordingly.	0.70
11/25/20	SKL	Prepare updated minimum cash analysis and circulate to J. Lowne (Purdue) and the PJT team prior to today's meeting.	1.10
11/25/20	SKL	Prepare updated scenarios for the Min. Cash Analysis	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		based on the feedback provided and circulate updated file to J. DelConte (AlixPartners) and H. Bhattal (AlixPartners) accordingly.	
11/25/20	SKL	Catch up with J. DelConte, S. Lemack and H. Bhattal (all AlixPartners) to review and discuss updates to the Min. Cash Analysis.	0.40
11/25/20	JD	Catch up with J. DelConte, S. Lemack and H. Bhattal (all AlixPartners) to review and discuss updates to the Min. Cash Analysis.	0.40
11/30/20	SKL	Create accounts payable release file.	0.80
11/30/20	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 11/27 cash report	1.90
Total			<u>217.30</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	93.20	515.00	47,998.00
Lan T Nguyen	107.70	515.00	55,465.50
HS Bhattal	10.30	840.00	8,652.00
Jesse DelConte	6.10	950.00	5,795.00
Total Hours & Fees	217.30		117,910.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
11/02/20	ADD	Compile information requested by Davis Polk as part of the transfer diligence process.	3.10
11/02/20	JD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin, G. Sim (all PJT) and M. Kesselman (Purdue) re: MSGE pre-call.	0.60
11/02/20	JD	Call with K. McClay (Caplan), M. Kesselman (Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: PBC overview and discussion.	1.20
11/03/20	JD	Review IMS data pulled together in response to diligence questions from FTI on Rhodes pipeline.	0.60
11/05/20	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP proposal.	0.20
11/05/20	ADD	Prepare and upload documents provided by Davis Polk's eDiscovery team for creditor committee review.	2.50
11/06/20	ADD	Review and follow up with outstanding diligence requests.	1.30
11/06/20	JD	Correspondence with FTI re: HRT diligence questions.	0.30
11/06/20	JD	Provide professional fee estimates to R. Brown (Purdue) for updated month end accruals.	0.40
11/09/20	JD	Review GTN by product files requested by FTI prior to requesting additional diligence info from management.	0.50
11/09/20	JD	Review inbound proposal from third party and correspondence with Davis Polk and PJT re: same.	0.50
11/09/20	JD	Correspondence with Davis Polk and AlixPartners team re: compensation summaries pulled together during SOFA/SOAL and investigation work.	0.30
11/09/20	ADD	Research AHC diligence request for gross profit of products data.	1.40
11/10/20	JD	Call with B. Bromberg, M. Diaz (both FTI), H. Schenk, G.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
11/10/20	JD	Coutts (both Houlihan), T. Melvin, J. Turner, G. Sim (all PJT) re: business plan forecast adjustments.	0.40
11/11/20	JD	Review information provided by Rhodes for open FTI diligence questions.	0.20
11/11/20	ADD	Correspondence with S. Lemack (AlixPartners) re: liquidation analysis.	1.20
11/12/20	ADD	Review outstanding Davis Polk diligence and follow up with client contacts.	1.50
11/12/20	ADD	Prepare and upload documents provided by Davis Polk's eDiscovery team to the data room for the creditor committee's review.	2.00
11/12/20	JD	Review outstanding Davis Polk diligence request and compile responsive materials.	2.40
11/13/20	JD	Meeting with K. Eckstein, R. Ringer (both Kramer Levin), S. Gilbert (Gilbert), M. Diaz, B. Bromberg (both FTI), S. Burian, G. Coutts, H. Schenk (all Houlihan), M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson, W. Curran (all Davis Polk), S. Birnbaum (Dechert), J. O'Connell, J. Turner, T. Melvin (all PJT) re: governance and corporate structure brainstorming.	1.60
11/16/20	JD	Meeting with A. Preis, S. Brauner, M. Hurley (all Akin Gump), M. Atkinson (Province), L. Szlezinger (Jefferies), M. Huebner, E. Vonnegut, B. Kamietzky, C. Duggan (all Davis Polk), S. Birnbaum (Dechert), M. Kesselman, R. Aleali (both Purdue), J. O'Connell, J. Turner (both PJT) re: UCC views on Sackler causes of action.	0.80
11/16/20	JD	Call with G. Coutts, S. Burian (both Houlihan), M. Diaz, B. Bromberg (both FTI), J. Turner, T. Melvin, R. Schnitzler (all PJT) re: go-forward business plan.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
11/16/20	JD	Review correspondence from DPW and Purdue re: DOJ settlement and other third party discussions.	0.20
11/16/20	JD	Review third party correspondence and materials provided.	0.60
11/16/20	JD	Correspondence with Davis Polk and PJT re: third party communications.	0.30
11/18/20	JD	Review updated third party diligence requests.	0.30
11/19/20	JD	Call with M. Atkinson (Province) re: third party discussions.	0.20
11/19/20	JD	Correspondence with A. DePalma (AlixPartners) and Purdue management re: FTI diligence requests.	0.30
11/19/20	JD	Correspondence with Davis Polk, Purdue management and PJT re: third party discussions.	0.50
11/19/20	JD	Call with M. Huebner (Davis Polk) re: discussions with Province.	0.10
11/19/20	JD	Call with E. Vonnegut (Davis Polk) re: third party discussions.	0.10
11/20/20	JD	Conversation with J. Turner, R. Schnitzler, T. Melvin (all PJT), G. Coutts (Houlihan), M. Diaz (FTI), M. Atkinson (Province), L. Szlezinger (Jefferies) and third party re: open questions.	0.80
11/23/20	JD	Call with D. Fogel, R. Haberin, V. Mancinelli (all Purdue), T. Melvin (PJT) re: Rhodes data requests.	0.40
11/23/20	JD	Review incoming diligence requests re: OTC in conjunction with information collected to date.	0.40
11/23/20	JD	Correspondence with Davis Polk, PJT and Purdue management re: third party discussions.	0.50
11/23/20	JD	Call with T. Melvin (PJT) re: Rhodes data requests.	0.20
11/23/20	ADD	Review diligence requests, prepare responses and compile	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		responsive materials.	
11/24/20	ADD	Request internal legal approval to share agreements with Noramco.	0.50
11/24/20	ADD	Compile and prepare files to send to Davis Polk's eDiscovery team for processing and designation.	0.70
11/24/20	ADD	Prepare Rhodes financial data summary schedule in response to creditor diligence request.	1.50
11/24/20	ADD	Review and update Purdue data room to save space for additional files.	0.80
11/24/20	ADD	Review RT contract list to identifying inactive and agreements expiring before year end.	2.00
11/24/20	JD	Call with M. Diaz, B. Bromberg (both FTI), G. Coutts, H. Schenk (both Houlihan), J. Turner, R. Schnitzler, T. Melvin, G. Sim (all PJT) re: business plan sensitivity.	0.80
11/24/20	JD	Correspondence with PJT and S. Lemack and H. Bhattal (AlixPartners) re: diligence materials for third party requests.	0.40
11/25/20	JD	Call with J. Turner, R. Schnitzler, T. Melvin (all PJT), M. Kesselman, R. Silbert (both Purdue), S. Birnbaum (Dechert), W. Colom, F. Blaudeau (both NAACP), M. Huebner, C. Robertson, J. McClammy, E. Vonnegut (all Davis Polk) re: side by side presentation.	1.40
11/25/20	JD	Correspondence with management re: Rhodes product diligence request.	0.20
11/25/20	JD	Correspondence with V. Mancinelli (Purdue) re: updated Rhodes product analysis.	0.30
11/25/20	ADD	Review RT contract list to identifying inactive and agreements expiring before year end.	1.40
11/25/20	ADD	Compile and prepare 2020 Rhodes Tech Spend data for	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		vendor relationship analysis.	
11/25/20	ADD	Add new Committee members provided by Davis Polk's diligence team to the virtual data room.	0.30
11/25/20	ADD	Prepare materials provided by Davis Polk's eDiscovery team for upload to the data room for Creditor Committee review.	0.90
11/25/20	ADD	Upload materials provided by Davis Polk's eDiscovery team to the data room for Creditor Committee review.	2.10
11/30/20	ADD	Work with PJT and Intralinks representative to open data room for new diligence work stream.	0.80
11/30/20	ADD	Compile and format documents in response to diligence requests in preparation for processing and upload to the data room.	1.50
11/30/20	ADD	Prepare materials provided by Davis Polk's eDiscovery team for upload to the dataroom for creditor committee review.	2.60
11/30/20	JD	Correspondence with PJT and Purdue management re: NAACP open diligence questions.	0.30
11/30/20	JD	Review list of open diligence items from FTI and status of requests internally.	0.70
11/30/20	JD	Review various IPD reports for Rhodes products requested by FTI.	0.50
11/30/20	JD	Correspondence with Purdue management, PJT and Davis Polk re: third party correspondence.	0.20
Total			50.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	30.20	515.00	15,553.00
Jesse DelConte	20.20	950.00	19,190.00
Total Hours & Fees	50.40		34,743.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/09/20	JD	Review breakdown of UST fees for the previous quarter and correspondence with US Trustee's office re: same.	0.20
11/10/20	SKL	Update the Purdue OCP payment tracker based on the latest OCP court filings provided by C. MacDonald (Purdue).	0.50
11/11/20	NAS	Review indemnification inputs for October 2020 insider payments MOR section.	0.40
11/11/20	JD	Review monthly Nalmefene court report prior to posting for advisors.	0.30
11/11/20	JD	Review correspondence from Davis Polk re: KEIP response to UST objections for upcoming hearing.	0.30
11/12/20	LTN	Prepare the cash activity section of the October monthly operating report	2.10
11/12/20	LTN	Prepare the professional fee payments section of the October monthly operating report	1.70
11/12/20	LTN	Prepare the bank account balances section of the October monthly operating report	1.80
11/17/20	LTN	Call with L. Nguyen, N. Simon (both AlixPartners) to review draft of insider payments section of October 2020 MOR.	0.50
11/17/20	LTN	Submit data requests to various Purdue teams for the insider payment sections of October MOR	0.70
11/17/20	LTN	Prepare the Insider payments section of October monthly operating report	2.00
11/17/20	NAS	Call with L. Nguyen, N. Simon (both AlixPartners) to review draft of insider payments section of October 2020 MOR.	0.50
11/17/20	NAS	Review all inputs and latest draft of insider payments section of October 2020 MOR.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
11/19/20	JD	Review and provide comments on the draft MOR.	0.30
11/19/20	LTN	Prepare October 2020 MOR and circulate for the internal sign-off	2.20
11/19/20	LTN	Call with A. DePalma and L. Nguyen (both AlixPartners) Re: MOR finalization	0.50
11/19/20	ADD	Review complete MOR draft in preparation for CFO review and signature.	1.90
11/19/20	ADD	Draft correspondence with outstanding items from 11/18 call with D. Sanil and A. Hart (both Purdue).	0.50
11/19/20	ADD	Review MRO follow up questions from CFO and research potentials responses.	1.30
11/19/20	ADD	Call with A. DePalma and L. Nguyen (both AlixPartners) Re: MOR finalization	0.50
11/20/20	LTN	Correspondence with J. Lowne (Purdue) reg IAC transactions and finalize MOR for review and signature	1.20
11/20/20	JD	Correspondence with L. Nguyen (AlixPartners) and Purdue management re: insider payment schedule of the MOR.	0.40
Total			21.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	4.20	515.00	2,163.00
Sam K Lemack	0.50	515.00	257.50
Lan T Nguyen	12.70	515.00	6,540.50
Nate A Simon	2.60	515.00	1,339.00
Jesse DelConte	1.50	950.00	1,425.00
Total Hours & Fees	21.50		11,725.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/01/20	JD	Finalize initial draft of LTRP and AIP forecast for discussion with management tomorrow.	1.80
11/02/20	JD	Call with J. Lowne and C. DeStefano (both Purdue) re: incentive compensation accounting.	0.40
11/02/20	GJK	Review alternatives analysis for Mundipharma, including potential bridges to next version of business plan.	1.50
11/02/20	GJK	Call with L. McCracken (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors to discuss request list following meeting with M. Princen (Mundipharma).	0.40
11/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to discuss Mundipharma diligence priorities for day.	0.30
11/02/20	NAS	Brainstorm potential additions to Mundipharma diligence report appendix.	0.80
11/02/20	NAS	Prepare for call with L. McCracken (Mundipharma).	0.30
11/02/20	NAS	Call with L. McCracken (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors to discuss request list following meeting with M. Princen (Mundipharma).	0.40
11/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss Mundipharma diligence priorities for day.	0.30
11/02/20	NAS	Draft Latin America slides for Mundipharma diligence report appendix.	1.80
11/02/20	NAS	Draft Southeast Asia slides for Mundipharma diligence report appendix.	1.40
11/02/20	NAS	Revise China slides in Mundipharma diligence report appendix.	1.10
11/02/20	JD	Call with J. Lowne (Purdue) re: Incentive comp.	0.30
11/02/20	JD	Call with J. Lowne, C. Landau, M. Kesselman, K. Gadski,	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		D. Rosen (all Purdue), T. Melvin, G. Sim (all PJT) re: branded sales 2021 budget.	
11/02/20	GJK	Coordinate and plan for updated diligence, including revised analysis for Appendix and prep for tax call.	2.00
11/02/20	JD	Review and provide comments on latest draft PBC deck.	0.40
11/02/20	JD	Update KEIP analysis of CEO and CFO compensation per previous KEIP deals. Correspondence with Davis Polk and Willis Towers Watson re: same.	0.70
11/02/20	JD	Correspondence with PJT, FTI and Purdue management re: open FTI diligence questions on HRT reports.	0.60
11/02/20	KM	Update Catalyst program dashboards re: project Catalyst.	2.10
11/02/20	KM	Analysis and planning re: tech transfer process for key APIs.	1.30
11/02/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	1.20
11/02/20	KM	Analysis re: API pricing impact on tech transfers costs.	0.80
11/02/20	KM	Call with J. Doyle and J. Giordano (both Purdue) re: API pricing for tech transfers.	0.50
11/02/20	KM	Meeting with S. Yates, S. Ashmann, J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - Quality.	1.00
11/02/20	ADD	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	
11/02/20	ADD	Meeting with S. Yates, S. Ashmann, J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - Quality.	1.00
11/02/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning and status discussion.	0.70
11/02/20	KM	Analysis re: quality activities timeline and impact of tech transfers.	0.50
11/02/20	KM	Call with D. Lundie, D. Fogel, J. Doyle, J. Lowne, D. McGuire, J. Giordano (all Purdue) re: API pricing per MSA for tech transfers.	0.50
11/02/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning and status discussion.	0.70
11/02/20	JD	Review final KERP file from D. Warren (Purdue) prior to her submitting it to payroll for processing.	1.50
11/02/20	JD	Review updated bonus accounting and long-term focus incentive comp files from J. Lowne (Purdue)	0.60
11/02/20	JD	Review and provide comments on the full September flash report and the version to be provided to creditors.	0.90
11/03/20	KM	Update project planning and management tracker re: project Catalyst transition.	1.10
11/03/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Doyle, J. Giordano, D. Fogel, R. Shamblen, W. DiNicola (all Purdue), B. Grubb (Noramco) re: 2021 Rhodes Tech Budget Review	2.00
11/03/20	KM	Call with A. DePalma and K. McCafferty (both	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners), J. Giordano, B. Evans, D. Eber, D. Fogel, J. Doyle, J. Peroni, J. Waltz, J. Fox, K. Kolar, R. Shamblen, V. Mancinelli, W. Addicks, D. McGuire (all Purdue) B. Grubb (Noramco) re: Product Transition and Forecasting Plan.	
11/03/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review.	2.40
11/03/20	KM	Meeting with A. Soma, A. Nadeau, J. Giordano (all Purdue), K. McCafferty and A DePalma (both AlixPartners) re: Noramco visit - RT operations transfer plan.	1.50
11/03/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), C. Yuh, M. Gibson, K. Ickes (both Skadden), D. Fogel, J. Doyle, J. Giordano, R. Shamblen, D. Lundie, S. McGuire, R. Aleali, J. Lowne, K. McCarthy (all Purdue) re: Project Catalyst - Revised Closing Checklist.	0.80
11/03/20	KM	Meeting with J. Doyle, A. Soma, A. Nadeau, P. Brinkerhoff, J. Giordano (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Noramco site visit - contracts.	1.10
11/03/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Doyle, J. Giordano, D. Fogel, R. Shamblen, W. DiNicola (all Purdue), B. Grubb (Noramco) re: 2021 Rhodes Tech Budget Review	2.00
11/03/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Giordano, B. Evans, D. Eber, D. Fogel, J. Doyle, J. Peroni, J. Waltz, J. Fox, K. Kolar, R. Shamblen, V. Mancinelli, W. Addicks, D. McGuire (all Purdue) B. Grubb (Noramco) re: Product Transition and Forecasting Plan.	1.00
11/03/20	ADD	Call with A. DePalma and K. McCafferty (both	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners), C. Yuh, M. Gibson, K. Ickes (both Skadden), D. Fogel, J. Doyle, J. Giordano, R. Shamblen, D. Lundie, S. McGuire, R. Aleali, J. Lowne, K. McCarthy (all Purdue) re: Project Catalyst - Revised Closing Checklist.	
11/03/20	ADD	Meeting with A. Soma, A. Nadeau, J. Giordano (all Purdue), K. McCafferty and A DePalma (both AlixPartners) re: Noramco visit - RT operations transfer plan.	1.50
11/03/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review.	2.40
11/03/20	ADD	Meeting with J. Doyle, A. Soma, A. Nadeau, P. Brinkerhoff, J. Giordano (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Noramco site visit - contracts.	1.10
11/03/20	JD	Review branded sales forecast presentation and data from yesterday's meeting in more detail.	0.50
11/03/20	JD	Participate in call with J. Lowne, C. Landau, M. Kesselman, R. Brown, M. Feltz (all Purdue), J. Turner, T. Melvin (both PJT) re: legal counsel 2021 budget.	0.70
11/03/20	JD	Review presentation for legal fee and general counsel 2021 budget amounts.	0.70
11/03/20	NAS	Review new diligence files provided by L. McCracken (Mundipharma).	1.30
11/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review updates to Appendix of draft Mundipharma diligence report.	0.70
11/03/20	NAS	Revise 2020 Performance section of draft Mundipharma diligence report to reflect updated figures through September.	2.20
11/03/20	NAS	Add comparison of September and June management	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		forecasts to Appendix of Mundipharma diligence report.	
11/03/20	NAS	Add background on announced Rafa transaction to Appendix of Mundipharma diligence report.	1.30
11/03/20	GJK	Review Mundipharma updated financials package.	2.00
11/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review updates to Appendix of draft Mundipharma diligence report.	0.70
11/03/20	GJK	Plan and coordinate Mundipharma diligence (ongoing).	2.00
11/04/20	GJK	Prepare for Mundipharma diligence calls and negotiation matrix planning.	2.00
11/04/20	GJK	Review Appendix versions, updates and source data.	1.50
11/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review revised Appendix to Mundipharma diligence report.	0.60
11/04/20	NAS	Add overview of items below EBITDA to draft Appendix of Mundipharma diligence report.	1.40
11/04/20	NAS	Add overview of Malta Perimeter to draft Appendix of Mundipharma diligence report.	0.70
11/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review revised Appendix to Mundipharma diligence report.	0.60
11/04/20	NAS	Correspondence with J. Turner (PJT) re: Rafa transaction announced.	0.30
11/04/20	JD	Call with J. Lowne, M. Kesselman, C. Landau, T. Garvey, J. Tran (all Purdue), J. Turner, T. Melvin, G. Sim (all PJT) re: Avrio 2021 budget.	0.80
11/04/20	JD	Review Avrio business plan slides and compare against previous business plan.	1.00
11/04/20	JD	Call with J. Lowne (Purdue) re: 2021 budgeting.	0.20
11/04/20	JD	Correspondence with Davis Polk and Purdue management	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: updates to the legal fee/general counsel budget.	
11/04/20	JD	Call with R. Aleali (Purdue) re: trust transfer process.	0.50
11/04/20	JD	Call with M. Huebner (Davis Polk) re: KEIP analysis.	0.20
11/04/20	JD	Update KEIP analysis per comments from M. Huebner (Davis Polk).	1.50
11/04/20	JD	Review and comment on draft responses from HRT on FTI diligence questions.	0.30
11/04/20	JD	Review updated KEIP/KERP guidance from management per discussions with Davis Polk.	0.30
11/04/20	JD	Review branded gross to net sales forecast details from E. Nowakowski (Purdue).	0.30
11/04/20	JD	Review latest transfer diligence checklist.	0.40
11/04/20	ADD	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - RT operations.	0.90
11/04/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), P. Brinkerhoff, E. Ruta, J. Doyle, J. Lima, A. Hart, D. Sanil (all Purdue) re: non-IT Contracts Discussion.	0.60
11/04/20	ADD	Meeting with P. Brinkerhoff, E. Ruta (both Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: RT IT Contracts Spreadsheet Review.	0.90
11/04/20	ADD	Meeting with A. Nadeau, J. Waltz, J. Gibbs, B. Evans, J. Fox, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - Supply Chain.	1.30
11/04/20	KM	Outstanding contract review analysis re: project Catalyst.	0.80
11/04/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), P. Brinkerhoff, E. Ruta, J. Doyle, J. Lima, A.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Hart, D. Sanil (all Purdue) re: non-IT Contracts Discussion.	
11/04/20	KM	Create flash report requests and materials re: project Catalyst.	1.20
11/04/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contracts.	1.80
11/04/20	KM	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - RT operations.	0.90
11/04/20	KM	Analysis re: required contract activities prior to close.	1.10
11/04/20	KM	Meeting with P. Brinkerhoff, E. Ruta (both Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: RT IT Contracts Spreadsheet Review.	0.90
11/04/20	KM	Meeting with A. Nadeau, J. Waltz, J. Gibbs, B. Evans, J. Fox, J. Giordano (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst transition - Supply Chain.	1.30
11/04/20	KM	Analysis re: API market pricing.	0.60
11/05/20	KM	Schedule next steps in project planning and management re: project Catalyst transition.	1.10
11/05/20	KM	Meeting with J. Doyle, E. Ruta, K. McCarthy (all Purdue), M. Gibson, A. Gallogly (both Skadden), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst Continuing Contracts Review.	0.70
11/05/20	KM	Update and refine workstream activities re: project Catalyst RT operations.	0.30
11/05/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) re: 2021 budget.	0.50
11/05/20	KM	Call with D. Fogel (Purdue) re: Catalyst MSA pricing	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		discussion.	
11/05/20	KM	Update and refine workstream activities re: project Catalyst quality and tech transfers.	2.20
11/05/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning and status discussion.	0.70
11/05/20	KM	Call with B. Purdon (Purdue) re: change control activities for Catalyst product transfers.	0.50
11/05/20	KM	Update and refine workstream activities re: project Catalyst finance and IT.	1.70
11/05/20	KM	Update and refine workstream activities re: project Catalyst Purdue transfers.	0.80
11/05/20	KM	Call with J. Giordano (Purdue) re: Catalyst Steering Committee meeting materials.	0.70
11/05/20	KM	Create and refine program dashboard re: project Catalyst.	1.30
11/05/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning and status discussion	0.70
11/05/20	ADD	Meeting with J. Doyle, E. Ruta, K. McCarthy (all Purdue), M. Gibson, A. Gallogly (both Skadden), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst Continuing Contracts Review.	0.70
11/05/20	JD	Weekly management update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, G. Koch, L. Donahue (all AlixPartners), J. O'Connell, T. Coleman, T. Melvin (all PJT).	0.90
11/05/20	JD	Correspondence with Davis Polk and FTI re: tax planning call.	0.30
11/05/20	JD	Correspondence with Davis Polk, Purdue management	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and Cigna re: payment timing.	
11/05/20	JD	Review latest liabilities subject to compromise analysis.	0.30
11/05/20	JD	Review business development presentation from yesterday's meeting.	0.40
11/05/20	NAS	Prepare for Mundipharma tax call with KPMG and other diligence advisors.	0.60
11/05/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma diligence advisors to discuss latest views on tax treatment.	1.00
11/05/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma diligence advisors to discuss latest views on tax treatment.	1.00
11/05/20	GJK	Plan and coordinate Mundipharma diligence including tax and fraudulent conveyance issues.	2.00
11/05/20	GJK	Weekly management update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, G. Koch, L. Donahue (all AlixPartners), J. O'Connell, T. Coleman, T. Melvin (all PJT).	0.90
11/05/20	NAS	Document takeaways following tax update call with KPMG and other Mundipharma diligence advisors.	0.20
11/05/20	LJD	Weekly management update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. DelConte, G. Koch, L. Donahue (all AlixPartners), J. O'Connell, T. Coleman, T. Melvin (all PJT).	0.90
11/06/20	NAS	Brainstorm potential assumption changed related to go-forward Mundipharma forecast.	2.00
11/06/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss open variables related to Mundipharma.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/06/20	NAS	Document notes and follow up items re: open variables related to Mundipharma following conversation with G. Koch (AlixPartners).	0.30
11/06/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to discuss open variables related to Mundipharma.	1.30
11/06/20	JD	Participate in meeting with J. Lowne, C. Landau, M. Kesselman, R. Fanelli, J. Ducharme (all Purdue), J. Turner, T. Melvin (both PJT) re: R&D 2021 forecast.	1.00
11/06/20	JD	Finalize updated 2020 and 2021 legal fee forecast for updated bankruptcy costs.	0.80
11/06/20	ADD	Meeting with V. Mancinelli, S. Engel (Purdue), J. Lowne, H. Ghanami, P. Brinkerhoff (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst IT transition.	1.00
11/06/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract (IT and non-IT) review.	2.30
11/06/20	KM	Update project Catalyst transition tracker.	1.10
11/06/20	KM	Meeting with V. Mancinelli, S. Engel (Purdue), J. Lowne, H. Ghanami, P. Brinkerhoff (all Purdue), K. McCafferty and A. DePalma (both AlixPartners) re: Catalyst IT transition.	1.00
11/06/20	KM	Update workstream dashboards re: project Catalyst.	1.70
11/06/20	KM	Prepare Steering Committee meeting materials and updates re: project Catalyst.	0.70
11/06/20	KM	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract (IT and non-IT) review.	2.30
11/07/20	JD	Correspondence with Davis Polk re: KEIP analysis.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/09/20	JD	Meeting with C. Landau, M. Kesselman, J. Lowne, D. Lundie, D. Fogel (all Purdue), J. Turner, T. Melvin, G. Sim (all PJT) re: 2021 RALP budget	1.00
11/09/20	JD	Meeting with C. Landau, J. Lowne, M. Kesselman, S. Robertson, B. Weingarten (all Purdue), J. Turner, T. Melvin (all PJT) re: Corporate communications 2021 budget meeting.	0.50
11/09/20	JD	HR 2021 budget meeting with C. Landau, J. Lowne, M. Kesselman, K. Laurel, R. Brown (all Purdue), J. Turner, T. Melvin, G. Sim (all PJT).	0.50
11/09/20	JD	Meeting with C. Landau, J. Lowne, M. Kesselman, M. Ronning, K. Gadski, D. Rosen (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) re: Commercial and Adhansia 2021 Budget	0.80
11/09/20	JD	Review and provide comments on draft sale considerations deck from PJT.	0.40
11/09/20	JD	Review details re: buyout offer.	0.50
11/09/20	JD	Review CF questions excel file from PJT prior to sharing with creditor advisors.	0.30
11/09/20	JD	Review presentation from J. Lowne (Purdue) re: PHI updated business plan.	0.80
11/09/20	JD	Review and comment on draft opioid board slides from J. Lowne (Purdue).	1.00
11/09/20	JD	Call with J. Lowne (Purdue) re: 2021 budget.	0.20
11/09/20	JD	Meeting with C. Landau, J. Lowne, M. Kesselman (all Purdue), T. Melvin, G. Sim (both PJT) re: 'CFO and IT functions 2021 Budget	0.20
11/09/20	JD	Medical Affairs 2021 budget call with J. Lowne, C. Landau, M. Kesselman, J. Ducharme, R. Fanelli, M. Kwarcinski (all Purdue), T. Melvin, J. Turner (both PJT).	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/09/20	GJK	Plan and coordinate Mundipharma diligence follow up items including tax meeting, appendix to report, and negotiations.	1.20
11/09/20	NAS	Respond to compensation data question from C. Oluwale (DPW).	0.70
11/09/20	NAS	Follow up with other Mundipharma diligence advisors re: tax call on 11/6.	0.50
11/09/20	NAS	Correspondence with J. Turner, J. Arsic, and I. Mian (all PJT) re: revised appendix to draft Mundipharma diligence report.	0.30
11/09/20	KM	Update analyses and presentation re: Catalyst Executive meeting deck.	1.90
11/09/20	KM	Update analyses and workplan re: Catalyst tech transfers.	1.70
11/09/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), and K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	0.80
11/09/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract status discussion.	0.70
11/09/20	KM	Catalyst transition program update re: workstream tracking.	1.20
11/09/20	KM	Prepare RT Operations workplan for sharing re: project Catalyst.	0.80
11/09/20	KM	Analysis re: external API pricing impact to MSA.	0.30
11/09/20	KM	Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, J. Lowne, J. Giordano (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Project Catalyst:	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/09/20	ADD	Steering Committee Meeting. Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Eber, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), and K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	0.80
11/09/20	ADD	Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, J. Lowne, J. Giordano (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Project Catalyst: Steering Committee Meeting.	1.50
11/09/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract status discussion.	0.70
11/10/20	ADD	Meeting with J. Giordano, B. Evans, A. Nadeau, J. Waltz, J. Fox, S. Engel, J. Narlis (all Purdue), and A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst Transition Team Meeting: Supply Chain.	0.70
11/10/20	ADD	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT Operations.	1.00
11/10/20	ADD	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.70
11/10/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract list status discussion.	0.50
11/10/20	KM	Analysis and project updates re: project Catalyst tech transfers.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/10/20	KM	Meeting with J. Giordano, B. Evans, A. Nadeau, J. Waltz, J. Fox, S. Engel, J. Narlis (all Purdue), and A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst Transition Team Meeting: Supply Chain.	0.70
11/10/20	KM	Analysis re: Catalyst impact of tech transfer timing.	0.80
11/10/20	KM	Meeting with D. Fogel, J. Giordano (both Purdue) re: Noramco/Purdue Executive Meeting agenda.	0.70
11/10/20	KM	Prepare presentation re: catalyst impact of financial changes.	0.80
11/10/20	KM	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT Operations.	1.00
11/10/20	KM	Analysis re: financial impact of volume changes to 2021 Catalyst projections.	1.20
11/10/20	KM	Call with D. Fogel (Purdue) re: Purdue/Noramco considerations analysis.	0.80
11/10/20	KM	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.70
11/10/20	JD	Correspondence with Davis Polk and AlixPartners team re: open KERP and KEIP questions.	0.60
11/10/20	JD	Correspondence with K. McCafferty (AlixPartners) re: cure costs.	0.20
11/10/20	JD	Review comments on draft updated business plan board slides from T. Melvin (PJT).	0.60
11/10/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract list status discussion.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/10/20	KM	Continue analysis re: financial impact of volume changes to 2021 Catalyst projections.	1.70
11/10/20	KM	Call with D. Fogel (Purdue) re: Purdue/Noramco considerations financial analysis.	0.60
11/11/20	KM	Update workplan re: project Catalyst transition.	0.60
11/11/20	KM	Meeting with D. Lundie, J. Lowne, J. Giordano (all Purdue) re: Purdue/Noramco meeting prep and analysis.	0.80
11/11/20	KM	Analysis re: assigned and excluded contracts for review with Noramco.	1.00
11/11/20	KM	Meeting with J. Giordano, A. Soma, E. Ruta, J. Lima, A. Nadeau, J. Doyle (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) S. Warner, B. Grubb (Noramco) re: Contract working session.	0.90
11/11/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract list status discussion and report generation.	2.30
11/11/20	KM	Call with D. Lundie (Purdue) re: Catalyst executive session with Noramco.	0.30
11/11/20	KM	Analysis re: YE inventory.	1.20
11/11/20	KM	Analysis re: Catalyst contracts for IT support.	1.50
11/11/20	JD	Review markup of Avrio business plan slides.	0.50
11/11/20	JD	Review trust transfer checklist prior to call with Davis Polk.	0.70
11/11/20	JD	Correspondence with Rhodes management re: contract assumption and rejection with regards to Rhodes Tech.	0.40
11/11/20	JD	Update latest professional fee tracker and send around to Davis Polk, Dechert and management.	0.80
11/11/20	JD	Update professional fee tracker and forecast for recently filed UCC fee apps.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/11/20	NAS	Review latest draft of Mundipharma diligence report.	0.30
11/11/20	GJK	Review diligence checklist	0.50
11/11/20	GJK	Review latest status of case as relates to settlement negotiations, transfer matters and potential Mundipharma negotiations.	1.00
11/11/20	GJK	Prepare for trust transfer process call	0.30
11/11/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract list status discussion and report generation.	2.30
11/11/20	ADD	Meeting with J. Giordano, A. Soma, E. Ruta, J. Lima, A. Nadeau, J. Doyle (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) S. Warner, B. Grubb (Noramco) re: Contract working session.	0.90
11/12/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	0.80
11/12/20	KM	Update tracker for project planning and management re: project Catalyst transition.	1.60
11/12/20	KM	Meeting with D. Fogel, W. DiNicola, B. Evans (all Purdue) re: financial impact of 2021 projections on Catalyst.	1.10
11/12/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	0.80
11/12/20	KM	Analysis re: 2021 forecast and inventory impact.	2.70
11/12/20	KM	Meeting with D. Fogel, W. DiNicola, B. Evans (all Purdue) re: 2021 demand and inventory projections for Catalyst.	0.70
11/12/20	KM	Analysis re: Noramco/PPLP executive meeting 2021	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		volume impact.	
11/12/20	KM	Call with D. Fogel (Purdue) re: Catalyst financials.	0.40
11/12/20	KM	Update Noramco/PPLP Exec meeting analysis re: 2021 forecast and inventory projections.	0.60
11/12/20	JD	Call with J. Turner, R. Schnitzler, T. Melvin (all PJT), E. Ruiz, D. Saussy, D. Rosen, L. Scheinbach (all Purdue) re: potential BD deal.	0.40
11/12/20	JD	Correspondence with Davis Polk, PJT and Purdue management re: third party discussions.	0.50
11/12/20	JD	Prepare summary of professional fees by month for Dechert.	0.40
11/12/20	JD	Review previous analyses re: min cash and other FTI and Houlihan diligence questions.	0.70
11/12/20	JD	Review deck from call with the AHC.	0.70
11/13/20	JD	Call with M. Diaz, B. Bromberg, S. Joffe (all FTI), H. Stoopack (Kramer Levin), B. Kelly (Brown Rudnick), T. Matlock, L. Altus, W. Curran (all Davis Polk), J. Turner, T. Melvin (both PJT), H. Bhattal and J. DelConte (both AlixPartners) re: post-emergence taxes.	0.50
11/13/20	JD	Call with C. Robertson (Davis Polk) re: tax planning.	0.10
11/13/20	JD	Correspondence with PJT re: Project Catalyst savings.	0.30
11/13/20	JD	Review UCC presentation re: Sackler causes of action.	1.00
11/13/20	JD	Review transfer presentation from Davis Polk to be given to the company to present to the executive committee.	0.30
11/13/20	JD	Review latest corporate scorecard in relation to the KEIP.	0.30
11/13/20	JD	Call with G. Koch, A. DePalma, J. DelConte (all AlixPartners), C. Robertson, A. Lele, E. Diggs (all Davis Polk) re: trust transfer process.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/13/20	JD	Review draft initial questions for third party.	0.20
11/13/20	KM	Call with J. Giordano (Purdue) re: Catalyst PMO discussion.	0.60
11/13/20	KM	Update Noramco/PPLP Exec meeting analysis re: buprenorphine forecast and inventory.	0.90
11/13/20	KM	Update Noramco/PPLP Exec meeting analysis re: methylphenidate forecast and inventory.	1.00
11/13/20	KM	Analysis and organization re: legal approval to review contracts with Noramco.	0.40
11/13/20	GJK	Prepare for call with DPW and AlixPartners to align on Transfer Matters work plan.	0.50
11/13/20	GJK	Call with G. Koch, A. DePalma, J. DelConte (all AlixPartners), C. Robertson, A. Lele, E. Diggs (all Davis Polk) re: trust transfer process.	0.50
11/13/20	GJK	Call with G. Koch KPMG, and other Mundipharma diligence advisors to discuss latest views on tax treatment.	1.00
11/13/20	GJK	Prepare and follow up for Mundipharma tax discussion.	1.00
11/13/20	GJK	Correspondence with A DePalma (AlixPartners) re PMO trackers.	0.50
11/13/20	ADD	Call with G. Koch, A. DePalma, J. DelConte (all AlixPartners), C. Robertson, A. Lele, E. Diggs (all Davis Polk) re: trust transfer process.	0.50
11/13/20	HSB	Call with M. Diaz, B. Bromberg, S. Joffe (all FTI), H. Stoopack (Kramer Levin), B. Kelly (Brown Rudnick), T. Matlock, L. Altus, W. Curran (all Davis Polk), J. Turner, T. Melvin (both PJT), H. Bhattal and J. DelConte (both AlixPartners) re: post-emergence taxes.	0.50
11/15/20	JD	Review and provide comments on draft diligence pack put	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		together by PJT.	
11/16/20	JD	Review materials re: vendor contract assumption calculations.	0.40
11/16/20	JD	Call with J. Lowne (Purdue) and J. Turner (PJT) re: follow up to AHC call.	0.50
11/16/20	JD	Review and provide comments on latest draft diligence packet.	0.70
11/16/20	JD	Review draft audited financial statements for 2016-2018 for Mundipharma.	0.70
11/16/20	JD	Correspondence with Purdue, Davis Polk and PJT re: third party discussions.	0.40
11/16/20	JD	Review comments from Purdue on draft diligence pack.	0.30
11/16/20	JD	Review revised third party diligence pack.	0.50
11/16/20	JD	Review draft correspondence from PJT prior to sending to the third party.	0.30
11/16/20	KM	Schedule project planning and management ongoing tasks re: project Catalyst transition.	1.50
11/16/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract status discussion.	0.80
11/16/20	KM	Tracking and reporting re: Catalyst contracts.	1.80
11/16/20	KM	Meeting with J. Giordano, B. Evans, A. Nadeau, J. Waltz, J. Fox, S. Engel, J. Narlis (all Purdue), and A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst Transition / Team Meeting: Supply Chain.	0.80
11/16/20	KM	Analysis and reporting re: Rhodes Technologies contracts.	2.60
11/16/20	KM	Update workplan and RAID logs re: supply chain transition.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/16/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract status discussion.	0.80
11/17/20	ADD	Call A. Nadeau, J. Lima, E. Ruta (both Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: IT vendor outreach.	0.60
11/17/20	ADD	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.50
11/17/20	ADD	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: IT vendor outreach.	0.90
11/17/20	ADD	Meeting with D. Lundie, D. Fogel, J. Doyle, J. Giordano, J. Lowne, R. Aleali, K. McCarthy (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners), M. Gibson, A. Gallogly (both Skadden) re: Amendments to Catalyst Documents.	1.40
11/17/20	ADD	Review DPW diligence request list and follow up with outstanding items.	1.60
11/17/20	ADD	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT Operations.	0.50
11/17/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract list status discussion.	0.90
11/17/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract list status discussion.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/17/20	KM	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT Operations.	0.50
11/17/20	KM	Update workplan and RAID logs re: RT operations transition.	0.50
11/17/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue), and K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	0.80
11/17/20	KM	Call A. Nadeau, J. Lima, E. Ruta (both Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: IT vendor outreach.	0.60
11/17/20	KM	Update executed contracts analysis re: project Catalyst.	1.70
11/17/20	KM	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.50
11/17/20	KM	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: IT vendor outreach.	0.90
11/17/20	KM	Call with D. Fogel (Purdue) re: inventory financial impact.	1.80
11/17/20	KM	Update workplan and RAID logs re: quality transition.	0.70
11/17/20	KM	Call with J. Giordano (Purdue) re: Catalyst transition update.	0.70
11/17/20	KM	Meeting with D. Lundie, D. Fogel, J. Doyle, J. Giordano, J. Lowne, R. Aleali, K. McCarthy (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners), M.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Gibson, A. Gollogly (both Skadden) re: Amendments to Catalyst Documents.	
11/17/20	JD	Correspondence with PJT, Davis Polk and Purdue re: third party discussions.	0.40
11/17/20	JD	Provide updated KEIP/KERP master file to reflect final KEIP agreement and updates from management.	0.40
11/17/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to provide background on transfer process workstream.	0.70
11/17/20	GJK	Review Project Catalyst PMO system for use in Transfer PMO.	2.00
11/17/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to provide background on transfer process workstream.	0.70
11/17/20	NAS	Review PMO files related to Project Catalyst workstream.	1.80
11/18/20	NAS	Review overview files related to transfer workstream.	1.40
11/18/20	NAS	Review Mundipharma audited financial statements 2016-2018.	0.70
11/18/20	NAS	Call with G. Koch (AlixPartners), N. Simon (AlixPartners), and S. Lemack (AlixPartners) to provide overview of Purdue transfer workstream.	0.40
11/18/20	NAS	Call with N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst PMO tracking files.	0.30
11/18/20	NAS	Create initial draft of Purdue transfer workstream workplan.	2.80
11/18/20	NAS	Call with G. Koch, K. McCafferty, N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst workplan.	0.40
11/18/20	NAS	Review comments to initial draft of transfer workplan.	0.20
11/18/20	GJK	Review SmartSheet set up for Transfer PMO.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/18/20	GJK	Call with G. Koch (AlixPartners), N. Simon (AlixPartners), and S. Lemack (AlixPartners) to provide overview of Purdue transfer workstream.	0.40
11/18/20	GJK	Call with G. Koch, K. McCafferty, N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst workplan.	0.40
11/18/20	SKL	Review and make updates to initial draft of Transfer Workplan prior to upcoming Transfer Workplan update call.	1.20
11/18/20	SKL	Call with G. Koch (AlixPartners), N. Simon (AlixPartners), and S. Lemack (AlixPartners) to provide overview of Purdue transfer workstream.	0.40
11/18/20	SKL	Call with N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst PMO tracking files.	0.30
11/18/20	SKL	Call with G. Koch, K. McCafferty, N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst workplan.	0.40
11/18/20	JD	Correspondence with internal AlixPartners team and FTI re: go forward tax modeling.	0.70
11/18/20	JD	Correspondence with PJT re: third party discussion.	0.40
11/18/20	JD	Review final October financials.	0.20
11/18/20	JD	Review comments from PJT on proposed Board slides.	0.50
11/18/20	JD	Review Benefit focus caused issues with Cigna.	0.30
11/18/20	KM	Analysis and presentation re: contracts status update for Noramco review.	2.20
11/18/20	KM	Call with P. Brinkerhoff (Purdue) re: PPLP contracts and status update.	0.90
11/18/20	KM	Meeting with J. Giordano, A. Soma, E. Ruta, J. Lima, A.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Nadeau, J. Doyle (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) M. Gibson, A. Gallogly (both Skadden), S. Warner, B. Grubb (both Noramco) re: Contract working session.	
11/18/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT agreements classification and review.	1.90
11/18/20	KM	Analysis re: tech transfer planning.	1.40
11/18/20	KM	Call P. Brinkerhoff (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: RT/Noramco IT Contracts.	0.90
11/18/20	KM	Call with D. Fogel (Purdue) re: project Catalyst.	0.10
11/18/20	KM	Call with G. Koch, K. McCafferty, N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst workplan.	0.40
11/18/20	KM	Update workplan re: project Catalyst.	1.70
11/18/20	KM	Update and refine workstream activities re: project Catalyst quality and contracts.	1.30
11/18/20	ADD	Review DPW diligence request list and follow up with outstanding items.	1.30
11/18/20	ADD	Meeting with J. Giordano, A. Soma, E. Ruta, J. Lima, A. Nadeau, J. Doyle (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) M. Gibson, A. Gallogly (both Skadden), S. Warner, B. Grubb (both Noramco) re: Contract working session.	0.70
11/18/20	ADD	Call P. Brinkerhoff (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: RT/Noramco IT Contracts.	0.90
11/18/20	ADD	Call with N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst PMO tracking files.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/18/20	ADD	Call with G. Koch, K. McCafferty, N. Simon, S. Lemack and A. DePalma (all AlixPartners) to provide overview of Project Catalyst workplan.	0.40
11/19/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contract status discussion.	0.40
11/19/20	KM	Update project planning and management tracker re: project Catalyst transition.	1.10
11/19/20	KM	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (both Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	0.80
11/19/20	KM	Analysis and tracking updates re: IT contracts for Catalyst.	1.20
11/19/20	KM	Call with K. McCafferty and J. DelConte (both AlixPartners) re: catch up on Project Catalyst and Rhodes business planning.	0.60
11/19/20	KM	Identify and update contracts re: Rhodes lab services and maintenance.	1.10
11/19/20	KM	Call A. Nadeau, J. Lima, E. Ruta (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	1.00
11/19/20	KM	Call S. Yates (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Rhodes Suppliers Meeting.	0.70
11/19/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT contract status discussion.	0.40
11/19/20	KM	Analysis and reporting re: open RT contracts and IT license agreements.	1.40
11/19/20	KM	Analysis and reporting re: IT agreements.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/19/20	JD	Participate in PPI board meeting pre-lunch break.	2.50
11/19/20	JD	Participate in post-lunch PPI board meeting.	1.60
11/19/20	JD	Review trust transfer considerations on payroll and benefits from Purdue payroll team.	0.30
11/19/20	JD	Correspondence with C. DeStefano (Purdue) re: retention payment calculations.	0.30
11/19/20	JD	Correspondence with Purdue payroll re: bonus forecasting.	0.40
11/19/20	JD	Call with J. Turner (PJT) re: third party discussions.	0.20
11/19/20	JD	Call with K. McCafferty and J. DelConte (both AlixPartners) re: catch up on Project Catalyst and Rhodes business planning.	0.60
11/19/20	JD	Internal AlixPartners discussions re: tax modeling workstream.	0.20
11/19/20	JD	Correspondence with A. DePalma (both AlixPartners) re: trust transfer work stream.	0.20
11/19/20	SKL	Review and reconcile latest Purdue transfer workstream tracker and prepare list of updates accordingly re: IP contracts.	0.90
11/19/20	LJD	Participate in post-lunch PPI board meeting.	1.60
11/19/20	LJD	Participate in PPI board meeting pre-lunch break.	2.50
11/19/20	GJK	Prepare for tax advisors meeting.	0.50
11/19/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma advisors re: latest takeaways from tax workstream.	0.90
11/19/20	GJK	Review draft of transfer work plan.	1.50
11/19/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: comments to initial draft of transfer workplan.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/19/20	NAS	Compare Mundipharma audited financials to figures provided by company.	0.50
11/19/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: comments to initial draft of transfer workplan.	0.50
11/19/20	NAS	Revise initial draft of transfer workplan following comments from G. Koch (AlixPartners).	3.20
11/19/20	NAS	Prepare for tax call with Mundipharma advisor group.	0.20
11/19/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma advisors re: latest takeaways from tax workstream.	0.90
11/20/20	NAS	Call with G. Koch, N. Simon and S. Lemack (all AlixPartners) to review latest draft of transfer workplan.	0.70
11/20/20	GJK	Review and edits to draft Transfer strawman workplan.	1.50
11/20/20	GJK	Plan and coordinate for Transfer PMO.	2.00
11/20/20	GJK	Call with G. Koch, N. Simon and S. Lemack (all AlixPartners) to review latest draft of transfer workplan.	0.70
11/20/20	SKL	Call with G. Koch, N. Simon and S. Lemack (all AlixPartners) to review latest draft of transfer workplan.	0.70
11/20/20	JD	Review materials in preparation of third party call.	0.50
11/20/20	JD	Call with R. Aleali, K. McCarthy (both Purdue), J. Turner, T. Melvin (both PJT), A. Lele, E. Diggs (both Davis Polk), J. DelConte and A. DePalma (both AlixPartners) re: open diligence questions.	0.60
11/20/20	JD	Review third party communications re: process.	0.40
11/20/20	JD	Review and provide comments on operating expense and Adhansia business plan slides from J. Lowne (Purdue).	1.50
11/20/20	JD	Review and provide comments on initial draft minimum cash analysis.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/20/20	JD	Review research and development and medical affairs forecast sensitivities from J. Lowne (Purdue).	0.60
11/20/20	JD	Correspondence with Houlihan and FTI re: follow up to discussions earlier this week on business planning.	0.40
11/20/20	JD	Review initial workplan created by N. Simon (AlixPartners) re: trust transfer process.	1.00
11/20/20	JD	Review initial draft diligence slides on the Wilson manufacturing facility.	0.30
11/20/20	KM	Review and distribution re: IT agreements tracking and reporting.	1.20
11/20/20	KM	Meeting with A. Nadeau, S. Yates, J. Ganley, E. Ruta, J. Lima, J. Giordano, K. McCarthy, P. Brinkerhoff (all Purdue) re: vendor outreach for IT agreements.	0.70
11/20/20	KM	Meeting with H. Ghnaimeh, J. Giordano, P. Brinkerhoff, A. Raina, S. Engel (all Purdue) re: IT weekly progress review.	0.80
11/20/20	KM	Analysis re: outstanding contracts for Catalyst.	0.70
11/20/20	KM	Analysis and reporting re: open RT contracts and IT license agreements.	2.50
11/20/20	KM	Call with J. Giordano (Purdue) re: Catalyst PMO updates.	0.20
11/20/20	KM	Review re: Catalyst workstream plans for implementation.	1.40
11/20/20	HSB	Call with R. Aleali, K. McCarthy (both Purdue), J. Turner, T. Melvin (both PJT), A. Lele, E. Diggs (both Davis Polk), J. DelConte and A. DePalma (both AlixPartners) re: open diligence questions.	0.60
11/22/20	JD	Review and provide comments on for profit pipeline and Avrio business plan slides.	1.30
11/22/20	NAS	Respond to question from C. Oluwale (DPW) re: 2018-2019 compensation schedules.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/23/20	NAS	Compare Mundipharma audited financials to figures provided by company.	0.90
11/23/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss Mundipharma tax workstream and priorities for day.	0.40
11/23/20	NAS	Review notes and schedule follow-up Mundipharma tax meeting with KPMG and Mundipharma diligence advisor group.	0.30
11/23/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to discuss Mundipharma tax workstream and priorities for day.	0.40
11/23/20	SKL	Catch up call with J. Turner, T. Melvin, R. Schnitzler (all PJT), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne (Purdue) re: open diligence requests.	0.80
11/23/20	JD	Catch up call with J. Turner, T. Melvin, R. Schnitzler (all PJT), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne (Purdue) re: open diligence requests.	0.80
11/23/20	JD	Call with J. Lowne (Purdue) re: business plan.	0.30
11/23/20	JD	Review schedule by product for Rhodes volume, sales and COGS projections.	0.30
11/23/20	JD	Develop new minimum cash analyses following conversation with J. Lowne (Purdue).	0.40
11/23/20	JD	Review and comment on the latest version of the minimum cash analysis.	0.80
11/23/20	JD	Correspondence with Purdue management and Davis Polk re: Purdue and Mallinckrodt ordinary course supply agreement.	0.30
11/23/20	JD	Review and comment on proposed email from PJT to third party.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
11/23/20	JD	Review updated North Carolina facility summary deck.	0.20
11/23/20	JD	Review correspondence re: Landau compensation calculations.	0.20
11/23/20	JD	Review comments from PJT on various business plan Board slide sections.	0.30
11/23/20	JD	Correspondence with management re: proposed diligence response for third party diligence requests.	0.30
11/23/20	JD	Review request for information from the FTC re: Project Catalyst. Correspondence with Purdue management and K. McCafferty (AlixPartners) re: same.	0.50
11/23/20	JD	Review potential materials that would be responsive to FTC request.	0.70
11/23/20	KM	Update project planning and management tasks re: project Catalyst transition.	1.70
11/23/20	KM	Call with D. Fogel (Purdue) re: Catalyst savings.	0.40
11/23/20	KM	Meeting with D. Lundie, D. Fogel, R. Shamblen, J. Doyle, J. Lowne, R. Aleali, K. McCarthy, J. Giordano (all Purdue), M. Gibson. A. Gallogly (both Skadden) re: Catalyst weekly update.	1.00
11/23/20	KM	Update tech transfers milestones, analyses and workplan re: project Catalyst.	1.40
11/23/20	KM	Update project management dashboard re: project Catalyst.	0.60
11/23/20	KM	Meeting with V. Mancinelli, J. Doyle, D. McGuire, J. Giordano (all Purdue) re: MSA schedule D.	0.20
11/23/20	KM	Update supply chain milestones and workplan re: project Catalyst.	0.80
11/23/20	KM	Meeting with J. Giordano, B. Evans, A. Nadeau, J. Waltz, J. Fox, S. Engel, J. Narlis (all Purdue) re: Project Catalyst	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Transition / Team Meeting: Supply Chain.	
11/23/20	KM	Develop contracts list re: Noramco-specific list for Catalyst.	2.30
11/23/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all Purdue) re: Catalyst transition - Noramco qualifications and Tech transfers.	1.00
11/23/20	HSB	Catch up call with J. Turner, T. Melvin, R. Schnitzler (all PJT), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne (Purdue) re: open diligence requests.	0.80
11/24/20	ADD	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.60
11/24/20	ADD	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT Operations.	0.80
11/24/20	KM	Locate and circulate documents re: FTC Nov. 20 request.	1.10
11/24/20	KM	Meeting with A. Soma, A. Nadeau, R. Shamblen, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - RT Operations.	0.80
11/24/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst Rhodes Tech contract status discussion.	0.20
11/24/20	KM	Analysis re: project Catalyst risks and issues impact.	2.20
11/24/20	KM	Update risks and issues analyses, logs and reports re:	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		project Catalyst.	
11/24/20	KM	Project planning and reporting re: project Catalyst transition.	1.40
11/24/20	KM	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.60
11/24/20	KM	Analysis and document preparation re: project Catalyst executed agreements for review.	1.60
11/24/20	JD	Review and provide comments on the updated minimum cash analysis.	1.00
11/24/20	JD	Prepare summary of Ad Hoc Committee professional fees to date per request from Davis Polk.	0.70
11/24/20	JD	Correspondence with A. DePalma (AlixPartners) re: Rhodes product analysis.	0.30
11/24/20	JD	Review opioid cash flow forecast analysis from the AHC.	0.40
11/24/20	JD	Review the latest HRT presentation to be shared with the creditors.	0.40
11/24/20	JD	Review materials pulled together in order to be responsive to the FTC.	0.80
11/24/20	JD	Review latest weekly sales report to be posted for creditor advisors.	0.30
11/24/20	JD	Correspondence with Davis Polk, PJT and Purdue management re: third party discussions.	0.50
11/24/20	GJK	Call with L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, T. Coleman, T. Melvin, J. Turner (all PJT) re: weekly check in and go-forward planning.	0.60
11/25/20	JD	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle,	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		J. Lowne (all Purdue), M. Gibson, A. Gallogly (both Skadden), R. Schnitzler (PJT), J. DelConte, K. McCafferty (both AlixPartners) re: FTC Nov 20 documents collection.	
11/25/20	JD	Correspondence with FTI re: tax modeling forecast.	0.30
11/25/20	JD	Collect information and review previous analysis re: expense rationalization slide for the business plan Board deck.	1.00
11/25/20	KM	Review milestone tracking re: Catalyst transition agreements.	1.20
11/25/20	KM	Analysis re: agreements for review with Noramco.	1.90
11/25/20	KM	Meeting with J. Giordano, A. Soma, E. Ruta, J. Lima, A. Nadeau, J. Doyle (Purdue) and A. DePalma and K. McCafferty (both AlixPartners) M. Gibson, A. Gallogly (Skadden), S. Warner, B. Grubb (Noramco) re: Contract working session.	0.50
11/25/20	KM	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	0.60
11/25/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), M. Gibson, A. Gallogly (both Skadden), R. Schnitzler (PJT), J. DelConte, K. McCafferty (both AlixPartners) re: FTC Nov 20 documents collection.	0.50
11/25/20	KM	Update and post executed contracts re: project Catalyst.	1.30
11/25/20	ADD	Meeting with J. Giordano, A. Soma, E. Ruta, J. Lima, A. Nadeau, J. Doyle (Purdue) and A. DePalma and K. McCafferty (both AlixPartners) M. Gibson, A. Gallogly (Skadden), S. Warner, B. Grubb (Noramco) re: Contract working session.	0.50
11/25/20	ADD	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	
11/27/20	JD	Correspondence with Purdue management re: Rhodes product diligence follow up.	0.30
11/30/20	JD	Call with J. Lowne (Purdue) re: retention plan.	0.30
11/30/20	JD	Call with D. Fogel, R. Haberin (both Purdue), T. Melvin (PJT) re: Product volume diligence request.	0.30
11/30/20	JD	Review latest weekly IMS data to be provided to creditors.	0.30
11/30/20	JD	Review and provide comments on updated PJT board slides.	0.50
11/30/20	JD	Update latest professional fee tracker per request from Davis Polk.	0.60
11/30/20	JD	Correspondence with Purdue management re: open Rhodes product volume questions.	0.20
11/30/20	JD	Correspondence with Purdue management and S. Lemack (AlixPartners) re: minimum cash analysis.	0.40
11/30/20	JD	Finalize final expense rationalization analysis and slides for business plan board presentation.	1.50
11/30/20	JD	Correspondence with Purdue management and PJT re: latest business plan analysis and sensitivities.	0.50
11/30/20	JD	Review latest Mundipharma tax analyses from KPMG.	0.90
11/30/20	JD	Review latest PHI deck and potential edits from PJT.	0.40
11/30/20	KM	Analyze progress to date and open tasks re: project Catalyst transition.	1.20
11/30/20	KM	Data management re: Catalyst savings and project plan.	0.90
11/30/20	KM	Call with J. Giordano (Purdue) re: Catalyst program	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		update.	
11/30/20	KM	Analysis re: quality agreements.	1.40
11/30/20	KM	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.70
11/30/20	KM	Update supply chain workplan and dashboard re: project Catalyst.	1.50
11/30/20	KM	Update reports re: Catalyst SteerCo meeting.	1.90
11/30/20	GJK	Review KPMG IAC tax analysis files.	2.00
11/30/20	GJK	Coordinate and follow up on Transfer PMO with Purdue, DPW and Alix.	1.30
11/30/20	NAS	Review most recent Mundipharma tax analysis provided by KPMG.	1.60
11/30/20	SKL	Call with A. DePalma, S. Lemack (both AlixPartners) re: Smartsheets.	0.20
11/30/20	ADD	Call with A. DePalma, S. Lemack (both AlixPartners) re: Smartsheets.	0.20
11/30/20	ADD	Meeting with S. Yates, S. Ashmann J. Northington, D. Eades, B. Purdon, J. Giordano (all Purdue) and A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition - Quality.	0.70
11/30/20	ADD	Correspondence with K. McCafferty (both AlixPartners) re: Project Catalyst Rhodes Tech contract status update.	0.30
11/30/20	ADD	Review and determine appropriateness of vendor invoice at the request of Purdue.	0.80
Total			385.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	46.20	515.00	23,793.00
Sam K Lemack	4.90	515.00	2,523.50
Nate A Simon	40.90	515.00	21,063.50
Gabe J Koch	41.60	840.00	34,944.00
HS Bhattal	1.90	840.00	1,596.00
Kevin M McCafferty	168.60	950.00	160,170.00
Jesse DelConte	76.50	950.00	72,675.00
Lisa Donahue	5.00	1,195.00	5,975.00
Total Hours & Fees	385.60		322,740.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
11/03/20	SKL	Continue to review and make updates to latest liquidation analysis working file.	1.80
11/03/20	SKL	Finalize updates to the debtor-by-debtor breakdown of asset values in the latest liquidation analysis.	2.10
11/04/20	HSB	Review DOJ settlement agreement details with regards to claims	0.50
11/05/20	HSB	Review description of Purdue's customer programs for purposes of evaluating assumptions & estimates for liquidations analyses	1.20
11/06/20	HSB	Working session with H. Bhattal, S. Lemack (both AlixPartners) to discuss latest edits and next steps to the liquidation analysis working file	0.70
11/06/20	HSB	Review details related to the liquidation analysis.	0.30
11/06/20	SKL	Working session with H. Bhattal, S. Lemack (both AlixPartners) to discuss latest edits and next steps to the liquidation analysis working file	0.70
11/09/20	SKL	Continue to update the liquidation analysis with the latest updates provided and begin preparing updated language for the draft.	1.60
11/09/20	HSB	Review inbound third party email on Project Plex	0.20
11/11/20	HSB	Review relevant sections of Coventry facility asset purchase agreement with regards to liquidation analysis	0.60
11/12/20	ADD	Call with A. DePalma, S. Lemack (both AlixPartners) re: Data requirements for liquidation analysis update.	0.70
11/12/20	ADD	Download updated balance sheet data from Purdue SAP accounting system for liquidation analysis refresh.	0.80
11/12/20	SKL	Call with A. DePalma, S. Lemack (both AlixPartners) re: Data requirements for liquidation analysis update.	0.70
11/12/20	SKL	Continue to update the draft liquidation analysis and	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		refreshing account balances based on the finalized October financials.	
11/12/20	JD	Correspondence with Purdue management re: liquidation analysis.	0.30
11/13/20	HSB	Review UCC Presentation deck with updates on settlement framework, discovery, estate causes of action and Sacklers' issues.	1.10
11/19/20	SKL	Continue to review latest feedback provided re: liquidation analysis, and update the analysis accordingly based on the updated 10/31/20 financials.	1.90
11/20/20	SKL	Continue to finalize updates to the latest liquidation analysis and circulate updates to R. Haberlin, D. Fogel and J. Carlisle (all Purdue).	2.10
11/23/20	SKL	Review latest recovery rates and updated assumptions provided by D. Fogel (Purdue) and team and prepare updates to the liquidation analysis accordingly.	2.40
11/23/20	JD	Review updated liquidation analysis sections from Purdue management.	0.50
11/24/20	SKL	Continue to finalize updates to the liquidation analysis with the updated 10/31 financials.	2.30
11/24/20	SKL	Discussion with H. Bhattal, S. Lemack (both AlixPartners) re: updates and next steps on liquidation analysis.	0.40
11/24/20	HSB	Discussion with H. Bhattal, S. Lemack (both AlixPartners) re: updates and next steps on liquidation analysis.	0.40
11/24/20	HSB	Review liquidation analysis updates provided by Purdue team	0.30
11/30/20	HSB	Review updated liquidation analysis and provided comments for updates	0.70
11/30/20	HSB	Review Coventry APA terms for updates to liquidation	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		analysis and provided comments.	
11/30/20	SKL	Continue to refresh the latest liquidation analysis with the 10/31 financials provided by B. Sielert (Purdue).	2.30
11/30/20	SKL	Update the liquidation analysis with the latest LSTC info.	0.80
11/30/20	SKL	Finalize review of updated recovery rates and assumptions provided by D. Fogel (Purdue) and prepare updates to the liquidation analysis accordingly.	1.90
11/30/20	SKL	Prepare reconciliation of updated recovery rates provided by D. Fogel (Purdue) and update the open items tracker accordingly.	0.60
11/30/20	SKL	Finalize remaining updates to the liquidation analysis based on the feedback provided and circulate updated analysis to D. Fogel, W. DiNicola, R. Haberlin and J. Carlisle (all Purdue).	2.50
Total			34.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: POR Development
Client/Matter # 012589.00107

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	1.50	515.00	772.50
Sam K Lemack	26.00	515.00	13,390.00
HS Bhattal	6.40	840.00	5,376.00
Jesse DelConte	0.80	950.00	760.00
Total Hours & Fees	34.70		20,298.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
11/02/20	ADD	Review and update master Rhodes Tech contract list and identify assigned and excluded contracts.	2.80
11/04/20	ADD	Identify Rhodes Tech IT agreements and update Rhodes Tech IT contract list.	1.40
11/04/20	ADD	Virtual working session A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contracts.	1.80
11/04/20	ADD	Calculate liabilities subject to compromise calculation for October month end.	2.20
11/05/20	ADD	Compile and upload Rhodes Tech agreements to the Project Catalyst data room for legal and Noramco review.	2.60
11/05/20	ADD	Review and classify Rhodes Tech contracts in preparation for Project Catalyst closing.	2.90
11/06/20	ADD	Review and classify Rhodes Tech contracts in preparation for Noramco review and Project Catalyst deal closing.	2.20
11/06/20	ADD	Compile and upload Rhodes Tech agreements to the Project Catalyst data room for legal and Noramco review.	2.30
11/06/20	KG	Stage and load two productions to Relativity. Stage and process documents for loading. Export and import data into Relativity. Perform quality control review of loaded data. Update/overlay data and index for search/retrieval.	2.30
11/09/20	ADD	Analyze Rhodes Tech IT relationships to understand ability to assign licenses.	2.50
11/09/20	ADD	Reconcile updated excluded contracts list with RT Master contracts list.	1.40
11/10/20	ADD	Download and organize Rhodes Tech vendor spend data from SAP accounting system.	0.80
11/10/20	ADD	Compile and upload Rhodes Tech agreements to the data room for Noramco's review.	2.40
11/10/20	ADD	Reconcile updated excluded contracts list with RT Master	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		contracts list.	
11/10/20	KG	Stage and load two productions to Relativity and update/overlay data and index for search/retrieval.	0.70
11/11/20	ADD	Review excluded contract list and compare to master contract list to identify potential updates.	2.40
11/11/20	ADD	Compile outstanding agreements and request approval from external counsel to share.	1.70
11/12/20	ADD	Review and redact Rhodes Tech contracts in preparation for upload to the dataroom for Noramco's review.	2.10
11/13/20	ADD	Review excluded contract list and compare to master contract list to identify potential updates.	2.70
11/13/20	ADD	Compile outstanding contracts and request approval from internal and external legal counsel to share.	2.20
11/16/20	ADD	Meeting with J. Giordano, B. Evans, A. Nadeau, J. Waltz, J. Fox, S. Engel, J. Narlis (all Purdue), and A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst Transition / Team Meeting: Supply Chain.	0.80
11/16/20	ADD	Review feedback from Rhodes Tech relationships managers on IT/Software contracts and update IT contract tracker.	2.60
11/16/20	ADD	Review Rhodes Tech Executed Contracts List and identify inconsistent entries and items for deletion.	2.50
11/16/20	ADD	Compile and upload Rhodes Tech agreements to the data room for legal review.	1.50
11/17/20	ADD	Review Post-Petition schedule and compare to Rhodes tech executed contract list to identify missing agreements.	2.60
11/17/20	ADD	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, E. Michalson, D. McGuire, J. Fox, W. Addicks, D. Eades, J. Giordano (all	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		Purdue), and K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst transition - Noramco qualifications and Tech transfers.	
11/18/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst IT agreements classification and review.	1.90
11/18/20	ADD	Call with S. Daniel, A. Hart (both Purdue) re: Rhodes Agreement Review.	0.40
11/18/20	ADD	Compile items submitted in response to creditor diligence request for upload to the data room and submit documents for Company approval.	1.50
11/19/20	ADD	Review Rhodes Tech contracts list and identify follow up items for the Rhodes Tech internal counsel.	2.00
11/19/20	ADD	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (both Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	0.80
11/19/20	ADD	Call A. Nadeau, J. Lima, E. Ruta (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting.	1.00
11/19/20	ADD	Call S. Yates (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Rhodes Suppliers Meeting.	0.70
11/24/20	ADD	Update RT master contract tracker with data provided by Noramco contract review team	1.60
11/24/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst Rhodes Tech contract status discussion.	0.20
11/24/20	ADD	Upload documents to the data room for Noramco's review.	0.30
11/25/20	ADD	Review contract list and other materials in preparation for	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		contract meetings with Noramco and external counsel.	
11/25/20	ADD	Upload materials to the Project Catalyst data room for review by external counsel.	0.70
11/30/20	ADD	Review Rhodes tech contract list and update IT agreement designations.	1.80
Total			65.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	62.70	515.00	32,290.50
Kristina Galbraith	3.00	645.00	1,935.00
Total Hours & Fees	65.70		34,225.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
11/25/20	NAS	Review Mallinckrodt disclosures for Purdue parties.	0.70
11/25/20	JD	Review Purdue disclosures for Mallinckrodt.	0.40
Total			1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Fee Recap:

Consultant	Hours	Rate	Amount
Nate A Simon	0.70	515.00	360.50
Jesse DelConte	0.40	950.00	380.00
Total Hours & Fees	1.10		740.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
11/03/20	TB	Update the thirteenth monthly fee statement for September 2020.	0.40
11/04/20	TB	Prepare Third Interim Fee Application.	2.50
11/04/20	TB	Update fee and expense status chart for Third Interim.	0.80
11/04/20	TB	Prepare Third Interim Fee Application and Exhibits.	2.30
11/04/20	MSM	Prepare professional fees for October 2020 fee application.	2.00
11/05/20	TB	Prepare Third Interim Fee Application and Exhibits.	0.70
11/05/20	KAS	Review draft third interim fee application.	1.30
11/06/20	MSM	Prepare professional fees for October 2020 fee application.	3.80
11/07/20	MSM	Prepare professional fees for October 2020 fee application.	3.90
11/11/20	TB	Update third interim fee application and exhibits.	1.60
11/11/20	JD	Review and provide comments on third interim AlixPartners fee application.	2.50
11/12/20	JD	Review and provide final comments on 3rd interim fee application for AlixPartners.	1.40
11/12/20	TB	Update third interim fee application and exhibits.	1.10
11/13/20	JD	Begin initial review of AlixPartners October fee application.	2.30
11/14/20	TB	Email to M. Pera, D. Consla, C. Robertson (all David Polk) attaching the third interim for filing with the court.	0.20
11/14/20	TB	Update fee and expense chart.	0.30
11/14/20	TB	Update third interim fee cover and fee application.	0.30
11/16/20	JD	Begin review of October fee application to be filed with the court.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
11/18/20	JD	Continue review of October fee application.	2.50
11/19/20	JD	Finalize final October fee application review.	0.50
11/23/20	JD	Review and comment on latest draft fee application.	0.20
11/23/20	TB	Prepare fourteenth monthly fee statement and exhibits for October 2020.	1.10
11/24/20	TB	Update fourteenth monthly fee statement and exhibits.	0.20
11/24/20	KAS	Review draft fourteenth fee application.	0.20
Total			33.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Melanie McCabe	9.70	415.00	4,025.50
Tammy Brewer	11.50	450.00	5,175.00
Kaitlyn A Sundt	1.50	510.00	765.00
Jesse DelConte	10.80	950.00	10,260.00
Total Hours & Fees	33.50		20,225.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
11/17/20	JD	Participate in court hearing on KEIP/KERP, Sackler DOJ settlement and 9019 DOJ settlement.	7.30
11/17/20	HSB	Call into November omnibus hearing re: KEIP, Sacklers' payment to DOJ and Debtors' settlement with DOJ	6.30
Total			13.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
HS Bhattal	6.30	840.00	5,292.00
Jesse DelConte	7.30	950.00	6,935.00
Total Hours & Fees	13.60		12,227.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/02/20	MFR	Review of request from Province re: Targin and royalties paid in 2010.	1.30
11/02/20	REO	Prepare summary of documented support re: foreign royalty income	0.80
11/02/20	REO	Review Box engagement folders re: support for transaction with IACs	1.20
11/02/20	RC	Review and respond to questions from Province re: royalties.	0.30
11/03/20	RC	Review information related to S. Baker's (Norton Rose) upcoming deposition and respond to DPW.	0.50
11/03/20	RC	Review information gathered in response to requests made by the UCC re: royalty information.	0.70
11/03/20	MFR	Review of request from Province re: Targin and royalties paid in 2010.	1.10
11/06/20	RC	Review additional support documentation gathered in response to requests from the UCC	1.10
11/06/20	RC	Review information gathered in response to diligence requests	1.00
11/09/20	RC	Review support documentation gathered in response to the UCC's distribution related requests.	1.40
11/09/20	RC	Additional review support documentation and provide comments to team in response to the UCC's distribution related requests.	1.60
11/09/20	RC	Review compensation information in response to requests from Davis Polk.	0.20
11/09/20	RC	Review tax distribution support documentation.	0.70
11/09/20	RC	Review Coventry distribution support and provide comments to team.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
11/09/20	RC	Review and analysis of transactions related to the 2017 reorganization	0.80
11/10/20	RC	Review tax support documentation in response to information requests.	1.20
11/13/20	RC	Review and respond to requests from DPW re: cash transfer of value report.	0.20
11/16/20	RC	Review information related to the cash distributions and respond to requests from Davis Polk.	1.30
11/16/20	SJC	Review and analysis of TXP tax estimation spreadsheets.	3.10
11/17/20	SJC	Review TXP tax estimation schedules to tax distributions.	3.00
11/17/20	RC	Review documentation gathered in response to requests made by the UCC's advisors.	0.40
11/18/20	RC	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) to discuss DPW distribution request.	1.00
11/18/20	RC	Review distribution related information in response to requests from counsel.	0.60
11/18/20	SJC	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) to discuss DPW distribution request.	1.00
11/18/20	SJC	Call with A. DePalma and S. Canniff (both AlixPartners) to discuss DPW distribution request requirements and next steps.	0.30
11/18/20	ADD	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) to discuss DPW distribution request.	1.00
11/18/20	ADD	Call with A. DePalma and S. Canniff (both AlixPartners) to discuss DPW distribution request requirements and next steps.	0.30
11/19/20	ADD	Call with A. DePalma and S. Canniff (both AlixPartners) to discuss DPW distribution request analysis.	0.30
11/19/20	SJC	Call with A. DePalma and S. Canniff (both AlixPartners) to	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		discuss DPW distribution request analysis.	
11/19/20	SJC	Create distribution summary for DPW (US partner cash distributions, Ex-US cash distributions, Purdue investment in associated companies, and Purdue tax distributions) for years 2017-2015.	3.00
11/19/20	SJC	Create distribution summary for DPW (US partner cash distributions, Ex-US cash distributions, Purdue investment in associated companies, and Purdue tax distributions) for years 2015-2012.	3.00
11/19/20	RC	Analysis of tax and non-tax distribution transactions	1.20
11/20/20	SJC	Create distribution summary for DPW (US partner cash distributions, Ex-US cash distributions, Purdue investment in associated companies, and Purdue tax distributions) for years 2012-2010.	3.00
11/23/20	SJC	Create distribution summary for DPW (US partner cash distributions, Ex-US cash distributions, Purdue investment in associated companies, and Purdue tax distributions) for years 2008 and 2009.	1.60
11/23/20	SJC	Review distribution summary for DWP, including US partner cash distributions, Ex-US cash distributions, Purdue investment in associated companies and Purdue tax distributions, for years 2008-2017 and compare totals to MDL and Report 1a.	2.10
11/23/20	SJC	Create distribution summary for DPW (Rhodes US partner cash distributions, Purdue cash distributions for Rhodes, and Rhodes tax distributions) for years 2008-2017.	3.00
11/23/20	RC	Review information related to executive compensation in response to requests from Davis Polk	0.20
11/23/20	RC	Review US distribution information	0.30
11/24/20	SJC	Working session with A. DePalma and S. Canniff (both	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		AlixPartners) re: DPW distribution request and summary.	
11/24/20	SJC	Review elimination and adjusting entries included in distribution summary for DPW.	1.70
11/24/20	SJC	Review distribution summary for DPW, including Rhodes US partner cash distributions, Purdue cash distributions for Rhodes and Rhodes tax distributions, for years 2008-2017 and compare totals to MDL and Report 1a.	2.00
11/24/20	SJC	Create summary analysis for Purdue and Rhodes distribution schedules for DPW.	2.50
11/24/20	ADD	Working session with A. DePalma and S. Canniff (both AlixPartners) re: DPW distribution request and summary.	0.60
11/25/20	RC	Review distribution analysis and related schedules	1.10
Total			53.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	2.00	420.00	840.00
Andrew D DePalma	2.20	515.00	1,133.00
Sam J Canniff	30.20	645.00	19,479.00
Mark F Rule	2.40	910.00	2,184.00
Richard Collura	16.80	1,090.00	18,312.00
Total Hours & Fees	53.60		41,948.00

Exhibit B

AlixPartners, LLP

Summary and Detailed Description of AlixPartners' Expenses

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2
Re: Expense
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
10/17/20	Conference Calls - - VENDOR: Vodafone US Inc	3.32
	Total Disbursements	3.32

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2130703-2
Re: Expense
Client/Matter # 012589.00150

Disbursement Recap:

Description	Amount
Other	3.32
Total Disbursements	3.32